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METHODS OF DETECTING AND 
CONTROLLING MUCOID PSEUDOMONAS 
BIOFILM PRODUCTION 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
The present application is a continuation of U.S. patent 
application Ser. No. 11/730,186, filed on Mar. 29, 2007, now 
U.S. Pat. No. 7,781,166 and claims the benefit of the filing 
date of U.S. Provisional Patent Application No. 60/787,497, 
filed Mar. 31, 2006, which is incorporated herein by reference 
in its entirety. 
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH AND 
DEVELOPMENT 
Statement under MPEP 310. The U.S. government has a 
paid-up license in this invention and the right in limited cir-
cumstances to require the patent owner to license others on 
reasonable terms as provided for by the terms of 
NNA04CC74G awarded by the National Aeronautics and 
Space Administration (NASA). 
Part of the work performed during development of this 
invention utilized U.S. Government funds. The U.S. Govern-
ment has certain rights in this invention. 
NAMES OF THE PARTIES TO A JOINT 
RESEARCH AGREEMENT 
Not Applicable. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the identification and use 
of positive regulators of alginate production in Pseudomonas 
aeruginosa. One aspect of the invention provides composi-
tions and methods for the early detection and diagnosis of the 
conversion to mucoidy of Pseudomonas aeruginosa. The 
present invention also provides a molecular mechanism for 
detecting the conversion from the nonmucoid to the mucoid 
state, including molecular probes for the early detection of 
this disease state. 
2. Background Art 
Cystic Fibrosis (CF) is the most common inheritable lethal 
disease among Caucasians. The leading cause of high mor-
bidity and mortality in CF patients are the chronic respiratory 
infections caused by Pseudomonas aeruginosa. Pseudomo-
nas aeruginosa is an aerobic, motile, gram-negative bacte-
rium with a simple metabolic demand that allows it to thrive 
in diverse environments. P. aeruginosa normally inhabits 
soil, water, and vegetation. Although it seldom causes disease 
in healthy people, P. aeruginosa is an opportunistic pathogen 
associated with fatal pneumonia in patients with CF, as well 
as patients with compromised immune systems and chronic 
infections such as non-cystic fibrosis bronchiectasis and uri-
nary tract infections. 
In CF patients, the initially colonizing P. aeruginosa 
strains are nonmucoid but in the CF lung, after a variable 
period, often one or two years, they inevitably convert into the 
mucoid form. Mucoid strains of P. aeruginosa grow as bio-
films in the airways of CF patients (Yu, H., and N. E. Head, 
Front Biosci. 7:D442-57 (2002)). Biofilms refer to surface-
attached bacterial communities encased in a glycocalyx 
matrix (Costerton, J. W., et al., Science 284:1318-22 (1999)). 
2 
Mucoid P. aeruginosa biofilms are microcolonies embedded 
in a capsule composed of copious amounts of alginate, an 
exopolysaccharide (Govan, J. R., and V. Deretic, Microbiol. 
Rev. 60:539-74 (1996)) and are resistant to host defenses 
5 (Ramsey, D. M., and D. J. Wozniak, Mol. Microbiol. 56:309-
22 (2005)). 
The emergence of mucoid strains of P. aeruginosa in CF 
lungs signals the beginning of the chronic phase of infection 
and is associated with further disease deterioration and poor 
to prognosis (Lyczak, J. B., et al., Clin. Microbiol. Rev. 15:194-
222 (2002)). The chronic phase of infection due to P. aerugi-
nosa is characterized by pulmonary exacerbations (fever, 
elevated white blood cell count, increased sputum produc-
tion, and decreased pulmonary function) that require antimi- 
15 crobial therapy (Miller, M. B., and Gilligan, P. H., J. Clin. 
Microbiol. 41:4009-4015 (2003)). CF exacerbations are typi-
cally interspersed with intervening periods of relative quies-
cence, with each phase lasting various lengths of time (Miller, 
M. B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015 
20 (2003)). However, lung function continuously declines, the 
infecting strains become increasingly resistant, and inevita-
bly, the patient succumbs to cardiopulmonary failure (Miller, 
M. B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015 
(2003)). 
25 	 There is a growing consensus that the lung pathology that 
occurs during chronic P. aeruginosa infection is due to a large 
extent to the immune response directed against pseudomonal 
biofilms (Miller, M. B., and Gilligan, P. H., J. Clin. Microbiol. 
41:4009-4015 (2003)). High levels of cytokines and leuko- 
30 cyte-derived proteases can be detected in airway fluid from 
CF patients and are believed to be responsible for much of the 
lung damage that occurs in this patient population (Miller, M. 
B., and Gilligan, P. H., J. Clin. Microbiol. 41:4009-4015 
(2003)). Alginate appears to protect P. aeruginosa from the 
35 consequences of this inflammatory response as it scavenges 
free radicals released by activated macrophages (Simpson, J. 
A., et al., Free Rad. Biol. Med. 6:347-353 (1989)). The algi-
nate mucoid coating also leads to the inability of patients to 
clear the infection, even under aggressive antibiotic therapies, 
40 most probably because it provides a physical and chemical 
barrier to the bacterium (Govan and Deretic, Microbiol. Rev. 
60:539-574 (1996)). 
Early aggressive antibiotic treatment of the initial coloniz-
ing non-mucoid P. aeruginosa population might prevent or at 
45 least delay chronic pulmonary infection. However, questions 
still remain as to whether such treatment should be performed 
routinely or only during pulmonary exacerbation, and 
whether the regimen could potentially lead to the emergence 
of resistant strains (Ramsey and Wozniak, Mol. Microbiol. 
5o 56:309-322 (2005)). Since P. aeruginosa is inherently resis-
tantto many antibiotics at concentrations that canbe achieved 
in vivo, with the exception of ciprofloxacin, those to which it 
is sensitive need to be given intravenously (Wilson and Dowl-
ing, Thorax 53:213-219 (1998)). However, long-term, 
55 aggressive antibiotic treatment is not without side effects. 
Therefore, it would be more beneficial to place the emphasis 
on aggressive treatment strategies before the in vivo switch to 
mucoidy since once chronic infection is established, it is 
rarely possible to eradicate it even with intensive, antibiotic 
60 therapy. Thus, early detection of conversion to mucoidy in 
patients is desired to allow aggressive therapy, thereby pre-
venting further disease deterioration. 
Synthesis of alginate and its regulation has been the object 
of numerous studies (Govan, J. R., and V. Deretic, Microbiol. 
65 Rev. 60:539-74 (1996); Ramsey, D. M., and D. J. Wozniak, 
Mol. Microbiol. 56:309-22 (2005)). Alginate production is 
positively and negatively regulated in wild-type cells. 
US 8,399,649 B2 
3 
Three tightly linked genes a1gU, mucA, and mucB have 
been previously identified with a chromosomal region shown 
by genetic means to represent the site where mutations cause 
conversion to mucoidy (see U.S. Pat. Nos. 6,426,187, 6,083, 
691, 5,591,838, and 5,573,910, incorporated herein by refer-
ence in their entireties). 
Positive regulation centers on the activation of the alginate 
biosynthetic operon (Govan, J. R., and V. Deretic, Microbiol. 
Rev. 60:539-74 (1996)). Positive regulators include the alter-
native stress-related sigma factorAlgU (Martin, D. W., et al., 
Proc. Natl. Acad. Sci. 90:8377-81 (1993)), also called A1gT 
(DeVries, C. A., and D. E. Ohman, J. Bacteriol. 176:6677-87 
(1994)), and transcriptional activators A1gR andAlgB, which 
belong to a bacterial two component signaling system. The 
cognate kinase ofA1gB is KinB (Ma, S., et al., J. Biol. Chem. 
272:17952-60 (1997)) whileAlgZ (Yu, H., et al., J. Bacteriol. 
179:187-93 (1997)) may be the kinase that phosphorylates 
A1gR. However, unlike a typical two-component system, 
alginate overproduction is independent of phosphorylation of 
A1gR or A1gB (Ma, S., et al., J. Bacteriol. 180:956-68 
(1998)). 
Negative regulation of alginate has focused on the post-
translational control of A1gU activity. In alginate regulation, 
the master regulator is A1gU and the signal transducer is 
MucA, a trans-inner membrane protein whose amino termi-
nus interacts with A1gU to antagonize the activity of A1gU, 
and the carboxyl terminus with MucB, another negative regu-
lator of alginate biosynthesis. The algUmucABC cluster is 
conserved among many Gram-negative bacteria. A1gU 
belongs to the family of extracytoplasmic function (ECF) 
sigma factors that regulate cellular functions in response to 
extreme stress stimuli. The action of ECF sigma factors is 
negatively controlled by MucA, MucB and MucC. This set of 
proteins forms a signal transduction system that senses and 
responds to envelope stress. 
MucA is the anti-sigma factor that binds A19U and antago-
nizes its transcriptional activator activity (Schurr, M. J., et al., 
J. Bacteriol. 178:4997-5004 (1996)). Consequently, inactiva-
tion of mucA in P. aeruginosa strain PAOI results in the 
mucoid phenotype (Alg+) (Martin, D. W., et al., Proc. Natl. 
Acad. Sci. USA 90:8377-81 (1993); Mathee, K., et al., Micro-
biology 145:1349-57 (1999)). Clinical mucoid isolates of P. 
aeruginosa carry recessive mutations in mucA (Anthony, M., 
et al., J. Clin. Microbiol. 40:2772-8 (2002); Boucher, J. C., et 
al., Infect. Immun. 65:3838-46 (1997)). The transition from a 
non-mucoid to mucoid variant occurs in concurrence with the 
mucA22 allele after exposure to hydrogen peroxide, an oxi-
dant in neutrophils (Mathee, K., et al., Microbiology 145: 
1349-57 (1999)). 
MucB is located in the periplasm in association with the 
periplasmic portion of MucA (Mathee, K., et al., J. Bacteriol. 
179:3711-20 (1997); Rowen, D. W., and V. Deretic, Mol. 
Microbiol. 36:314-27 (2000)). MucC is a mild negative regu-
lator whose action is in synergy with MucA or MucB 
(Boucher, J. C., et al., Microbiology 143:3473-80 (1997)). 
MucD is a negative regulator whose dual functions include 
periplasmic serine protease and chaperone activities that are 
thought to help remove misfolded proteins of the cell enve-
lope for quality control (Boucher, J. C., et al., J. Bacteriol. 
178:511-23 (1996); Yorgey, P., et al., Mol. Microbiol. 
41:1063-76 (2001)). 
Overproduction of alginate is an important virulence factor 
for bacterial biofilm formation in vivo. Alginate protects the 
bacterium from oxidative stress by scavenging the reactive 
oxygen species (Learn, D. B., et al., Infect. Immun. 55:1813-8 
(1987); Simpson, J. A., et al., Free Radic. Biol. Med. 6:347-53 
(1989)). 
4 
There is a significant and urgent need in hospitals and 
clinical laboratories for a rapid, sensitive and accurate diag- 
nostic test for detection of potential conversion to mucoidy of 
P. aeruginosa prior to the detection of the emergence of a 
5 mucoid colony morphology on a growth plate in a laboratory. 
BRIEF SUMMARY OF THE INVENTION 
The present invention describes the identification and use 
to of mucE, a positive regulator of alginate production in P. 
aeruginosa. Induction of mucE causes mucoid conversion in 
P. aeruginosa. 
One object of this invention is to provide compositions for 
15 the early detection and diagnosis of the conversion to 
mucoidy of Pseudomonas aeruginosa. The present invention 
also provides molecular probes to detect the conversion from 
the nonmucoid to the mucoid state, via Northern blot, RT-
PCR, or real-time RT-PCR, including diagnostic kits for the 
20 early detection of this disease state. 
Another object of this invention is to provide methods for 
the early detection and diagnosis of the conversion to 
mucoidy of Pseudomonas aeruginosa. One method for 
detecting a cell converted to mucoidy involves obtaining a 
25 cell sample suspected of conversion to mucoidy, contacting 
messenger RNA from the cell sample with a mucE nucleic 
acid segment, and detecting the presence of increased hybrid-
ized complexes, wherein the presence of increased hybrid-
ized complexes is indicative of conversion to mucoidy. A six 
30 fold increase of mucE messenger RNA is sufficient to cause 
conversion to mucoidy in mucA+ wild type cells. Thus, early 
detection of conversion to mucoidy is possible by detecting 
and measuring mucE expression as compared to the baseline 
35 expression level of mucE in non-mucoid cells. 
Early detection for the trend of increased expression of the 
mucE message in various samples, including the sputum 
samples from patients with cystic fibrosis, samples from 
patients carrying endotracheal tubes, and urinary tract cath- 
40 eters would provide an indication that the colonizing bacteria 
has started to enter the biofilm mode of growth, thereby 
requiring immediate administration of aggressive antibiotic 
therapy. 
A further embodiment of thi s invention are the use of MucE 
45 antibodies and methods of using MucE antibodies for detect-
ing the conversion to mucoidy of P. aeruginosa. 
A further embodiment of this invention is a method for 
preventing the conversion to mucoidy of P. aeruginosa by 
blocking mucE expression or MucE activity. Mucoid P. 
5o aeruginosa biofilms can be formed via two means: the muta-
tions in mucA (see U.S. Pat. Nos. 6,426,187, 6,083,691, and 
5,591,838), and increased expression of mucE. mucE acts 
upstream of mucA, thus, the control of mucoidy mediated by 
mucE occurs before the mucA mutation. Therefore, inhibi- 
55 tion of MucE activity provides a means to prevent conversion 
to mucoidy during the early stage of bacterial colonization. 
In still further embodiments, the present invention con-
cerns a method for identifying new compounds that inhibit 
mucE gene expression or MucE function, which may be 
60 termed "candidate substances." Such compounds may 
include anti-sense oligonucleotides or molecules that block 
or repress the mucE promoter, or molecules that directly bind 
to MucE to block the activity of MucE. 
The present invention also provides for a method for 
65 screening a candidate substance for preventing P. aeruginosa 
conversion to mucoidy comprising contacting E. coli bacteria 
with an effective amount of a candidate substance; and assay- 
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ing for reporter gene activity, wherein a decrease in the 	 suppressor mutant while FRD2-VEI is like VEl with the 
expression of the reporter gene indicates inhibition of mucE 
	
insertion in the a1gU promoter. VE3-NMI to -NM4 are the 
promoter activity. 	 spontaneous nonmucoid mutants with suppressors inactivat- 
Another object of the present invention is A1gW, a positive 	 ing a1gU. VE3NM3+algU: pUCP20-algU in trans. VE22: 
regulator for alginate production, and the use of A1gW as a 5 cupB5 +Oe and VE24: oprL+ but with reduced expression of 
potential drug target. 	 oprL due to production of the antisense RNA. 
FIG. 9 shows the regulatory cascade of alginate production 
BRIEF DESCRIPTION OF THE 
	
in P. aeruginosa. A1gU is the alginate-specific sigma factor, 
DRAWINGS/FIGURES 	 whose activity is antagonized by anti-sigma factor, MucA. 
io MucAis an inner membrane protein with its C-terminus inthe 
The following drawings form part of the present specifica- 	 periplasm, and its N-terminus interacting with A1gU in cyto- 
tion and are included to further demonstrate certain aspects of 	 plasm. The alginate operon consists of 12 genes encoding 
the present invention. The invention may be better understood 
	
biosynthetic enzymes, thus collectively termed "alginate 
by reference to one or more of these drawings in combination 	 engine." The enzymes A1gI, A1g7, and A1gF are involved in 
with the detailed description of specific embodiments pre-  15 O-acetylation of alginate. AlgK is needed for formation of the 
sented herein. 	 alginate polymer and A1gE for the export of alginate across 
FIG.1 shows the nucleotide sequence of mucE in P. aerugi- 	 the membrane. 
nosa (SEQ ID NO: 1). The mucE gene is an unclassified ORE 	 FIG. 10 is a map of the expression vector pUCP20-Gm- 
(PA4033) in the genomes of PAOI and PA14. It encodes a 	 mucE. The expression vector contains the coding region of 
small peptide of 89 amino acids with a molecular mass of 9.5 20 the mucE gene driven by a promoter derived from the gen- 
kDa. 	 tamicin (Gm) cassette of pFAC. This promoter is highly 
FIG. 2 shows the amino acid sequence of MucE in P. 	 expressive in P. aeruginosa. This construct can render the 
aeruginosa (SEQ ID NO:2). MucE has a predicted N-tenni- 	 nonmucoid PAOI mucoid while the control backbone vector 
nal leader peptide of 36 amino acids, which is likely to direct 	 without mucE has no effect on the phenotype. 
the native peptide of MucE to the inner membrane for pro-  25 FIG. 11 shows an alignment of the mucE homologs iden- 
cessing and export to the periplasm or outer membrane of P. 	 tified from the completed andpartially completed genomes of 
aeruginosa. The WVF at the C-terminus is the signal for 	 three species within the genus of Pseudomonas. The three 
alginate induction. 	 species are PA: Pseudomonas aeruginosa; PF: Pseudomonas 
FIG. 3 shows the nucleotide sequence of the homolog of 
	 fluorescens; and PS: Pseudomonas syringae. The strains 
mucE in P. fluorescence Pf-5 (SEQ ID NO:3). 	 30 shown are: PA-PAOI (SEQ ID NO: 23), Pseudomonas 
FIG. 4 shows the amino acid sequence of the homolog of 	 aeruginosa PAOI (causes opportunistic infections in 
MucE in P. fluorescence Pf-5 (SEQ ID NO:4). 	 humans); PA-PA14 (SEQ ID NO: 22), Pseudomonas aerugi- 
FIG. 5 shows the number of mariner transposon insertions 	 nosa UCBPP PA14 (human clinical isolate); PA-2192 (SEQ 
per TA site in the a1gU promoter region of four strains of P. 	 ID NO: 20), Pseudomonas aeruginosa 2192 (CF patient iso- 
aeruginosa. FIG. 5A shows the frequency of the insertions in 35 late); PA-C3719 (SEQ ID NO: 21), Pseudomonas aeruginosa 
each P. aeruginosa strain. FIG. 5B shows the sequence of the 	 C3719 (unknown source but probably clinical origin); PS- 
a1gU promoter region (SEQ ID NO: 16) containing all TA 	 PPH (SEQ ID NO: 26), Pseudomonas syringae pv. phaseoli- 
sites with an assigned number matching to FIG. 5A. 	 cola 1448A (causes halo blight on beans); PS-PTO (SEQ ID 
FIG. 6 shows the levels of alginate, A1gU and MucB in P. 	 NO: 27), Pseudomonas syringae pv. tomato DC3000 (bacte- 
aeruginosa mucoid mutants caused by induction of algUmu-  4o rial speck disease on tomato plants); PS-SB728 (SEQ ID NO: 
cABC in comparison with the wild type PAOI (B). FIG. 6A 	 28), Pseudomonas syringae pv. syringae B728a (brown spot 
shows the amounts of alginate (µg alginate/mg protein) that 	 disease on beans); PF-PF5 (SEQ ID NO: 24), Pseudomonas 
were measured for 4-72 h. Asterisk indicates significant dif- 	 fluorescens Pf-5 (Saprophyte) (the production of a number of 
ferences at P<0.05 in comparison with the same time point in 	 antibiotics as well as the production of siderophores by this 
PAOl . FIG. 6B is a Western blot analysis of the total protein 45 strain can inhibit phytopathogen growth); and PF-PFOI 
extracts from the same cells as above were probed by anti- 	 (SEQ ID NO: 25), Pseudomonas fluorescens PfO-1 (micro- 
A1gU (Schorr, M. 7., et al., J. Bacteriol. 178:4997-5004 	 organism of putrefaction and well adapted to soil environ- 
(1996)) and anti-MucB (Boucher, J. C., et al., J. Bacteriol. 	 ments). 
178:511-23 (1996)) monoclonal antibodies. The genotype of 	 FIG. 12 shows an alignment of the algal homologs identi- 
each mutant is shown. The number below each blot was the 50 fied from the completed and partially completed genomes of 
ratio of internally normalized protein relative to the level of 	 three species within the genus of Pseudomonas. The three 
PAOI at the same timepoint. The +oe superscriptused in FIG. 	 species are PA: Pseudomonas aeruginosa; PF: Pseudomonas 
6A refers to the overexpression of the a1gU mucABC operon. 	 fluorescens; and PS: Pseudomonas syringae. All these spe- 
FIG. 7 shows the levels of alginate, the expression ofA1gU 	 cies have the capacity to overproduce alginate. The strains 
and MucB in VE2 (PAOI mucE +Oe) as detected by Western 55 shown are the same as for FIG. 11, and include A1gW 
blots (FIG. 7A) and RT-PCB (FIG. 713). Bacterial cells were 	 homologs for PA-2192 (SEQ ID NO: 29), PA-C3719 (SEQ 
grown under the same conditions as described in Methods, 	 ID NO: 30), PA-PA14 (SEQ ID NO: 31), PA-PAOI (SEQ ID 
and were subjected to the same treatments as in FIG. 6. 	 NO: 32), PF-PF5 (SEQ ID NO: 33), PF-PFOI (SEQ ID NO: 
Asterisk in alginate production indicates significant differ- 	 34), PS-PPH (SEQ ID NO: 35), PS-PTO (SEQ ID NO: 36), 
ences compared with PAOI at the same time point as in FIG. 6o and PS-SB728 (SEQ ID NO: 37). The predicted functional 
6. The ratio of internally normalizedAlgU and MucB to those 	 domains of A1gW include an N-terminal signal peptide 
of PAOI is shown. in FIG. 7B indicates the RT minus con- 	 sequence at amino acids 1-27, a trypsin domain (peptidase 
trols. 	 activity, serine at A1gW 227 is conserved) at amino acids 
FIG. 8 shows upregulation ofAlgU in VE13 (PAOI kinB-) 	 114-260, and a PDZ domain at amino acids 270-380. 
(FIG. 8A) in association with increased alginate production. 65 	 FIG. 13 shows the detection of N-terminal His-tag labeled 
FIG. 813: Western blots showing the levels ofA1gU and MucB 
	
MucE protein via Western Blot with anti-penta-his mono- 
in various mutants after 24 h growth. FRD2 carries the a1gT18 	 clonal antibody and SDS-PAGE with Coomassie blue. 
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FIG. 14 shows the sequence of mucE (SEQ ID NO: 2; 	 findings, A1gW is a positive regulator for alginate production. 
amino acid sequence of mucE) and the phenotypes of the 	 The algW gene and A1gW protein, the algW homologs, and 
different translational mucE-phoA fusions (SEQ ID NO: 17; 	 the uses thereof as described above for the P. aeruginosa 
nucleic acid sequence of the full-length mucE-phoA fusion). 	 mucE gene and MucE protein are also part of the present 
The location of the mariner transposon bearing the aacCI 5 invention. 
gene conferring Gm" in the chromosome of the mucoid 
	 Another object of this invention are mucA mucoid mutants 
mutants PAOI VE2 and PA14DR4 is shown. Different lengths 	 and the use of these mutants to screen for suppressors and 
of mucE sequences were fused with phoA without the leader 	 potential toxin genes. Mucoid mutants with mucA mutations 
signal peptide sequence to demonstrate the effect of the signal 
	 (see U.S. Pat. Nos. 6,426,187, 6,083,691, and 5,591,838) 
sequence on translocation across the inner membrane to the io have been previously detected from clinical specimens. The 
periplasm. 1. Negative control, no 5' leader peptide sequence 	 presence of these mutations is a poor prognosticator and 
(no sig phoA); 2. Positive control, the wild-type E. coli phoA 	 represents the onset of chronic infection. Since the elevation 
leader sequence restored in the construct by directly fusing it 	 of mucE can cause the emergence of mucoid P. aeruginosa 
with phoA (Ec wt-phoA); 3. Full-length mucE-phoA; 4. 	 before mucA mutations occur, the involvement of mucE in 
mucE with the predicted N-terminal leader sequence fused 15 alginate induction is upstream of mucA. 
with phoA; 5. partial mucE N-terminal leader sequence fused 
	 Another object of this invention is to provide methods for 
with phoA; 6. C-terminal mucE with ATG fused with phoA. 	 the early detection and diagnosis of the conversion to 
The exact phoA fusion sites are as indicated in the mucE 	 mucoidy of Pseudomonas aeruginosa. One method for 
sequence. The leader sequence of mucE with max cleavage 	 detecting a cell converted to mucoidy involves obtaining a 
site is between pos. 36 (P) and 37 (A) (box). 	 20 biological specimen suspected of conversion to mucoidy, 
FIG. 15 shows an alignment of MucP (SEQ ID NO: 19) and 	 contacting messenger RNA from the specimen with a mucE 
the Escherichia coli orthologue RseP (SEQ ID NO: 18). 	 nucleic acid segment, and detecting the presence of increased 
Identical amino acids are marked by an asterisk (*). The two 	 hybridized complexes, wherein the presence of increased 
terminal protease domains are shown in light gray and the two 	 hybridized complexes over baseline is indicative of conver- 
PDZ domains are shown in medium gray. The overlapping 25 sion to mucoidy. 
region containing both a portion of the protease domain and a 	 The biological specimen to be assayed for the presence of 
portion of the PDZ domain is shown in dark gray. 	 mucoid P. aeruginosa can be prepared in a variety of ways, 
depending on the source of the specimen. The specimen may 
DETAILED DESCRIPTION OF THE INVENTION 
	
be obtained from the following: patients with debilitated 
30 immune systems, sputum samples from patients with pneu- 
Infections due to P. aeruginosa are recognized by the medi- 	 monia, endotracheal samples from intubating patients under 
cal community as particularly difficult to treat. In particular, 	 intensive care, samples from urinary catheters, samples from 
the emergence of a mucoid phenotype of P. aeruginosa in CF 	 wounds, and especially from patients suffering from cystic 
lungs is associated with further disease deterioration and poor 	 fibrosis. Specimens may be a sample of human blood, spu- 
prognosis. A patient's prognosis for recovery from an infec-  35 turn, wound exudate, endotracheal samples, respiratory 
tion caused by mucoid P. aeruginosa is enhanced when the 	 secretions, human tissues (e.g., lung) or a laboratory culture 
diagnosis is made and appropriate treatment initiated as early 	 thereof, and urine. Since alginate induction is synonymous 
in the course of infection as possible before the number of 	 with biofilm formation in vivo, the increased expression of 
bacteria in the host becomes overwhelming and much more 	 mucE may also be used to monitor the biofilm formation in a 
difficult to bring under control. Thus, early detection of P. 40 confined environment during space travel (astronauts). 
aeruginosa conversion to mucoidy in patients is particularly 	 A further embodiment of this invention is the use of MucE 
desired to allow aggressive therapy, thereby preventing fur- 	 antibodies and methods of using MucE antibodies for detect- 
ther disease deterioration. 	 ing the conversion to mucoidy of P. aeruginosa via ELISA or 
The present application describes the identification of a 	 other immunoassays. 
positive regulator involved in alginate and biofilm production 45 	 A further embodiment of this invention is a method for 
in P. aeruginosa, termed mucE (SEQ ID NOs:1-2) (GenBank 	 preventing the conversion to mucoidy of P. aeruginosa. In 
accession numbers DQ352561 (PAOI mucE) and DQ352562 	 particular, the present invention concerns methods for iden- 
(PA14 mucE)). Induction of mucE causes mucoid conversion 	 tifying new compounds that inhibit mucE gene expression or 
in P. aeruginosa. 	 MucE function, which may be termed "candidate sub- 
One object of this invention is to provide compositions for 50 stances." Such compounds may include anti-sense oligo-
the early detection and diagnosis of the conversion to 	 nucleotides or molecules that block or repress the mucE pro- 
mucoidy of Pseudomonas aeruginosa in biological speci- 	 moter. 
mens. By "early detection" is meant detecting P. aeruginosa 	 Specifically, when the last three amino acids of MucE are 
conversion to mucoidy using certain assay methods, includ- 	 changed from WVF to other combinations, the majority of 
ing but not limited to, methods involving the use of a nucleic 55 altered signals are ineffective to induce mucoid biofilm pro- 
acid probe or antibodies, 1 to 14 days, specifically 1 to 10 
	
duction, indicating the specificity of this signal in mucoid 
days, more specifically 1 to 7 days, and most specifically 6 	 conversion. Thus, WVF is an important signal for mucoid 
days, 5 days, 4 days, 3 days, 2 days, 24 hours, 18 hours, 12 
	
biofilm formation in P. aeruginosa. This WVF signal plays a 
hours or 8 hours before detecting the emergence of a mucoid 	 role in the bacterium's ability to overproduce alginate and 
colony morphology on a growth plate in a laboratory. 	 60 enter a biofilm mode of growth via regulated proteolysis as 
The present invention also provides molecular probes to 	 depicted in FIG. 9. The present invention provides for meth- 
detect the conversion from the nonmucoid to the mucoid 	 ods to employ the signal as a drug target. Diagnostic kits to 
state, including via Northern blot, RT-PCR, or real-time RT- 	 screen for the presence of the signal in patients with chronic 
PCR, including diagnostic kits for the early detection of this 	 P. aeruginosa infections are contemplated. In addition, meth- 
disease state. 	 65 ods to screen for compounds that inhibit the function of this 
The present invention is also directed to algW and the use 	 signal are also contemplated. Such compounds will have a 
of A1gW as a potential drug target. Contrary to previous 	 specific anti-biofilm function. 
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The present invention also provides for a method for 	 the relevant sequences could also be used. Sequences of non- 
screening a candidate substance for preventing P. aeruginosa 	 translated DNA may be present 5' or 3' from the open reading 
conversion to mucoidy comprising contacting E. coli bacteria 	 frame, where the same do not interfere with manipulation or 
with an effective amount of a candidate substance; and assay- 	 expression of the coding regions. 
ing for reporter gene activity, wherein a decrease in the 5 	 The term "nucleotide sequence" refers to a heteropolymer 
expression of the reporter gene indicates inhibition of mucE 	 of deoxyribonucleotides. DNA sequences encoding the pro- 
promoter activity. 	 teins of this invention can be assembled from fragments and 
MucE homologs from other Pseudomonas species or 	 short oligonucleotide linkers, or from a series of oligonucle- 
strains are also contemplated (see FIG. 11). ThesePseudomo- 	 otides, to provide a synthetic gene which is capable of being 
nas species and strains include PA-PAOI, Pseudomonas io expressed in a recombinant transcriptional unit. 
aeruginosa PAOI (causes opportunistic infections in 	 The term "recombinant expression vector" refers to a rep- 
humans); PA-PA14, Pseudomonas aeruginosa UCBPP PA14 	 licable DNA construct used either to amplify or to express 
(human clinical isolate); PA-2192, Pseudomonas aeruginosa 	 DNA which encodes the recombinant proteins of the present 
2192 (CF patient isolate); PA-C3719, Pseudomonas aerugi- 	 invention and which includes a transcriptional unit compris- 
nosa C3719 (unknown source but probably clinical origin); 15 ing an assembly of (1) a genetic element or elements having 
PS-PPH, Pseudomonas syringae pv. phaseolicola 1448A 	 a regulatory role in gene expression, for example, promoters 
(causes halo blight on beans); PS-PTO, Pseudomonas syrin- 	 or enhancers, (2) a structure or coding sequence which is 
gae pv. tomato DC3000 (bacterial speck disease on tomato 	 transcribed into mRNA and translated into protein, and (3) 
plants); PS-SB728, Pseudomonas syringae pv. syringae 	 appropriate transcription and translation initiation and termi- 
B728a (brown spot disease onbeans); PF-PF5, Pseudomonas 2o nation sequences. Structural elements intended for use in 
fluorescens Pf-5 (Saprophyte) (the production of a number of 	 yeast expression systems preferably include a leader 
antibiotics as well as the production of siderophores by this 	 sequence enabling extracellular secretion of translated pro- 
strain can inhibit phytopathogen growth); and PF-PFOI, 	 tein by a host cell. Alternatively, where recombinant protein is 
Pseudomonas fluorescens PfO-1 (microorganism of putre- 	 expressed without a leader or transport sequence, it may 
faction and well adapted to soil environments). The mucE 25 include an N-terminal methionine residue. This residue may 
homologs and the use thereof as described above for the P. 	 optionally by subsequently cleaved from the expressed 
aeruginosa mucE gene and MucE protein are also part of the 	 recombinant protein to provide a final product. 
present invention. 	 As used herein, the term "expression vector" refers to a 
Isolated polynucleotides comprising fragments containing 	 construct made up of genetic material (i.e., nucleic acids). 
one or more mucE consensus regions are also contemplated. 3o Typically, a expression vector contains an origin of replica- 
The consensus regions are shown in FIG. 11. 	 tion which is functional in bacterial host cells, e.g., Escheri- 
By "isolated" polynucleotide is intended a nucleic acid 	 chia coli, and selectable markers for detecting bacterial host 
molecule, DNA or RNA, circular or linear, which has been 	 cells comprising the expression vector. Expression vectors of 
removed from its native environment. For example, recom- 	 the present invention contain a promoter sequence and 
binant DNA molecules contained in a vector are considered 35 include genetic elements as described herein arranged such 
isolated for the purposes of the present invention. Further 	 that an inserted coding sequence can be transcribed and trans- 
examples of isolated DNA molecules include recombinant 	 lated in prokaryotes or eukaroytes. In certain embodiments 
DNA molecules maintained in heterologous host cells or 	 described herein, an expression vector is a closed circular 
purified (partially or substantially) DNA molecules in solu- 	 DNA molecule. 
tion. 	 40 	 The term "expression" refers to the biological production 
The term "positive regulator" as used herein, means that 	 of a product encoded by a coding sequence. In most cases, a 
the induction of expression and/or activity of such a gene 	 DNA sequence, including the coding sequence, is transcribed 
encoding a functional protein causes alginate overproduction. 	 to form a messenger-RNA (mRNA). The messenger-RNA is 
Examples of positive regulators include a1gU, mucE, and 	 then translated to form a polypeptide product which has a 
algal. 	 45 relevant biological activity. Also, the process of expression 
The term "negative regulator" as used herein, means that 	 may involve further processing steps to the RNA product of 
the absence of such a gene encoding a functional protein 	 transcription, such as splicing to remove introns, and/or post- 
causes alginate overproduction. Examples of negative regu- 	 translational processing of a polypeptide product. 
lators include kinB, mucA, mucB, and mucD. 	 The term "recombinant microbial expression system" 
The term "recombinant," as used herein, means that a pro-  50 means a substantially homogeneous monoculture of suitable 
tein is derived from recombinant (e.g., microbial) expression 	 host microorganisms, for example, bacteria such as E. coli or 
systems. The term "microbial" refers to recombinant proteins 	 yeast such as S. cerevisiae, which have stably integrated a 
made in bacterial or fungal. (e.g., yeast) expression systems. 	 recombinant transcriptional unit into chromosomal DNA or 
As a product, the term "recombinant microbial" defines a 	 carry the recombinant transcriptional unit as a component of 
protein produced in a microbial expression system which is 55 a resident plasmid. Generally, cells constituting the system 
essentially free of native endogenous substances. Protein 	 are the progeny of a single ancestral transformant. Recombi- 
expressed in most bacterial cultures, e.g., E. coli, will be free 	 nant expression systems as defined herein will express heter- 
of glycan. 	 ologous protein upon induction of the regulatory elements 
The term "DNA sequence" refers to a DNA polymer, in the 	 linked to the DNA sequence or synthetic gene to be 
form of a separate fragment or as a component of a larger 60 expressed. 
DNA construct. Preferably, the DNA sequences are in a quan- 	 One embodiment of the present invention is a method of 
tity or concentration enabling identification, manipulation, 	 detecting conversion to mucoidy in Pseudomonas aerugi- 
and recovery of the sequence and its component nucleotide 	 nosa in a biological specimen comprising detecting MucE 
sequences by standard biochemical methods, for example, 	 expression. A preferred embodiment is a method of detecting 
using a cloning vector. Such sequences are preferably pro-  65 conversion to mucoidy in Pseudomonas aeruginosa having 
vided in the form of an open reading frame uninterrupted by 	 an active mucE gene product comprising the detection of the 
internal nontranslated sequences. Genomic DNA containing 	 mucE messenger RNA in a sample suspected of conversion to 
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mucoidy. In this case, the sequence encodes an active gene 
product and the sequence is detected by hybridization with a 
complementary oligonucleotide, to form hybridized com-
plexes. The presence of increased hybridized complexes is 
indicative of conversion to mucoidy in Pseudomonas aerugi- 5 
nosa. The complementary oligonucleotides may be 
5'-TCAAAACACCCAGCGCAACTCGTCACG-3', (SEQ 
ID NO:5) 5'-AGTAGCGAAGGACGGGCTGGCGGT-3', 
(SEQ ID NO:6) or 5'-TTGGCTAACTGGCCGGAAAC-
CCAT-3' (SEQ ID NO:7). 10 
A further embodiment of the present invention is the use of 
MucE antibodies and methods of using MucE antibodies for 
detecting the conversion to mucoidy of P. aeruginosa or for 
inhibiting MucE function. 15 
In still further embodiments, the present invention con-
cerns a method for identifying new compounds that inhibit 
transcription from the mucE promoter, which may be termed 
as "candidate substances." Such compounds may include 
anti-sense oligonucleotides or molecules that encourage 20 
repression of the mucE promoter. The present invention pro-
vides for a method for screening a candidate substance for 
preventing P. aeruginosa conversion to mucoidy comprising: 
contacting E. coli bacteria with an effective amount of a 
candidate substance; and assaying for reporter gene activity, 25 
wherein a decrease in the expression of the reporter gene 
indicates inhibition of MucE promoter activity. 
In additional embodiments, the present invention also con-
cerns a method for detecting mucoid Pseudomonas aerugi-
nosa bacterium in a biological sample. The method comprises 30 
reacting a sample suspected of containing P. aeruginosa with 
a detergent, EDTA, and a monoclonal antibody or fragment 
thereof capable of specifically binding to MucE expressed by 
P. aeruginosa, separating the sample from unbound mono- 35 
clonal antibody; and detecting the presence or absence of 
immune complexes formed between the monoclonal anti-
body and MucE. 
Polynucleotides 
The DNA sequences disclosed herein will also find utility 40 
as probes or primers in nucleic acid hybridization embodi-
ments. Nucleotide sequences of between about 10 nucle-
otides to about 20 or to about 30 nucleotides, complementary 
to SEQ ID NOs:1-4, will find particular utility, with even 
longer sequences, e.g., 40, 50, 100, even up to full length, 45 
being more preferred for certain embodiments. The ability of 
such nucleic acid probes to specifically hybridize to mucE-
encoding sequences will enable them to be of use in a variety 
of embodiments. For example, the probes can be used in a 
variety of assays for detecting the presence of complementary 50 
sequences in a given sample. However, other uses are envi-
sioned, including the use of the sequence information for the 
preparation of mutant species primers, or primers for use in 
preparing other genetic constructions. 
Nucleic acid molecules having stretches of 10, 15, 20, 30, 55 
50, or even of 100 nucleotides or so, complementary to SEQ 
ID NOs:l and 3, will have utility as hybridization probes. 
These probes will be useful in a variety of hybridization 
embodiments, such as Southern and Northern blotting in 
connection with analyzing the complex interaction of struc- 60 
tural and regulatory genes in diverse microorganisms and in 
clinical isolates from patients, including CF patients. The 
total size of fragment, as well as the size of the complemen-
tary stretch(es), will ultimately depend on the intended use or 
application of the particular nucleic acid segment. Smaller 65 
fragments will generally find use in hybridization embodi-
ments, wherein the length of the complementary region may 
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be varied, such as between about 10 and about 100 nucle-
otides, according to the complementary sequences one 
wishes to detect. 
The use of a hybridization probe of about 10 nucleotides in 
length allows the formation of a duplex molecule that is both 
stable and selective. Molecules having complementary 
sequences over stretches greater than 10 bases in length are 
generally preferred, though, in order to increase stability and 
selectivity of the hybrid, and thereby improve the quality and 
degree of specific hybrid molecules obtained. One will gen-
erally prefer to design nucleic acid molecules having gene-
complementary stretches of 15 to 20 nucleotides, or even 
longer where desired. Such fragments may be readily pre-
pared by, for example, directly synthesizing the fragment by 
chemical means, by application of nucleic acid reproduction 
technology, such as the Polymerase Chain Reaction (PCR) 
technology of U.S. Pat. No. 4,603,102 (herein incorporated 
by reference) or by introducing selected sequences into 
recombinant vectors for recombinant production. 
Accordingly, the nucleotide sequences of the invention 
may be used for their ability to selectively form duplex mol-
ecules with complementary stretches of homologous, or het-
erologous genes or cDNAs. Depending on the application 
envisioned, one will desire to employ varying conditions of 
hybridization to achieve varying degrees of selectivity of 
probe towards target sequence. For applications requiring 
high selectivity, one will typically desire to employ relatively 
stringent conditions to form the hybrids, e.g., one will select 
relatively low salt and/or high temperature conditions, such as 
provided by 0.02 M-0.15 M NaCl at temperatures of 50° C. to 
70° C. Such selective conditions tolerate little, if any, mis-
match between the probe and the template or target strand, 
and would be particularly suitable for isolating functionally 
related genes. 
In certain instances, for example, where one desires to 
prepare mutants employing a mutant primer strand hybrid-
ized to an underlying template or where one seeks to isolate 
specific mutant mucE-encoding sequences from related spe-
cies, functional equivalents, or the like, less stringent hybrid-
ization conditions will typically be needed in order to allow 
formation of the heteroduplex. In these circumstances, one 
may desire to employ conditions such as 0.15 M-0.9 M salt, at 
temperatures ranging from 20'C. to 55° C. Cross-hybridizing 
species can thereby be readily identified as positively hybrid-
izing signals with respect to control hybridizations. In any 
case, it is generally appreciated that conditions can be ren-
dered more stringent by the addition of increasing amounts of 
formamide, which serves to destabilize the hybrid duplex in 
the same manner as increased temperature. Thus, hybridiza-
tion conditions can be readily manipulated, and thus will 
generally be a method of choice depending on the desired 
results. 
In certain embodiments, it will be advantageous to employ 
nucleic acid sequences of the present invention in combina-
tion with an appropriate means, such as a label, for determin-
ing hybridization. A wide variety of appropriate indicator 
means are known in the art, including fluorescent, radioac-
tive, enzymatic, biotinylated, and chemiluminescent labels, 
which are capable of giving a detectable signal. Fluorophores, 
luminescent compounds, radioisotopes and particles can also 
be employed. In preferred embodiments, one will likely 
desire to employ a fluorescent label or an enzyme tag, such as 
urease, alkaline phosphatase or peroxidase, instead of radio-
active or other environmental undesirable reagents. In the 
case of enzyme tags, calorimetric indicator substrates are 
known which can be employed to provide a means visible to 
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the human eye or spectrophotometrically, to identify specific 
hybridization with complementary nucleic acid-containing 
samples. 
In general, it is envisioned that the hybridization probes 
described herein will be useful both as reagents in solution 5 
hybridization as well as in embodiments employing a solid 
phase. In embodiments involving a solid phase, the test DNA 
(or RNA) is adsorbed or otherwise affixed to a selected matrix 
or surface. This fixed, single-stranded nucleic acid is then 
subjectedto specific hybridization with selectedprobes under io 
desired conditions. The selected conditions will depend on 
the particular circumstances based on the particular criteria 
required (depending, for example, on the G+C contents, type 
of target nucleic acid, source of nucleic acid, size of hybrid-
ization probe, etc.). Following washing of the hybridized 15 
surface so as to remove nonspecifically bound probe mol-
ecules, specific hybridization is detected, or even quantified, 
by means of the label. 
Longer DNA segments will often find particular utility in 
the recombinant production of peptides or proteins. DNA 20 
segments which encode peptide antigens from about 15 to 
about 50 amino acids in length, or more preferably, from 
about 15 to about 30 amino acids in length are contemplated 
to be particularly useful. DNA segments encoding peptides 
will generally have a minimum coding length in the order of 25 
about 45 to about 150, or to about 90 nucleotides. 
The nucleic acid segments of the present invention, regard-
less of the length of the coding sequence itself, may be com-
bined with other DNA sequences, such as promoters, addi-
tional restriction enzyme sites, multiple cloning sites, other 30 
coding segments, and the like, such that their overall length 
may vary considerably. It is contemplated that a nucleic acid 
fragment of almost any length may be employed, with the 
total length preferably being limited by the ease of prepara-
tion and use in the intended recombinant DNA protocol. For 35 
example, nucleic acid fragments may be prepared in accor-
dance with the present invention which are up to 10,000 base 
pairs in length, with segments of 5,000, 3,000, 2,000 or 1,000 
base pairs being preferred and segments of about 500 base 
pairs in length being particularly preferred. 40 
It will be understood that this invention is not limited to the 
particular nucleic acid and amino acid sequences of SEQ ID 
NOs:I and 3. Therefore, DNA segments prepared in accor-
dance with the present invention may also encode biologi-
cally functional equivalent proteins or peptides which have 45 
variant amino acids sequences. Such sequences may arise as 
a consequence of codon redundancy and functional equiva-
lency which are known to occur naturally within nucleic acid 
sequences and the proteins thus encoded. Alternatively, func-
tionally equivalent proteins orpeptides maybe created via the 50 
application of recombinant DNA technology, in which 
changes in the protein structure may be engineered, based on 
considerations of the properties of the amino acids being 
exchanged. 
Further embodiments of the invention include vectors 55 
comprising polynucleotides, which comprise a nucleotide 
sequence at least 95% identical, and more preferably at least 
96%, 97%, 98% or 99% identical, to any of the nucleotide 
sequences of the vectors comprising polynucleotides 
described above. 60 
Other embodiments of the invention include polynucle-
otides, which comprise a nucleotide sequence at least 95% 
identical, and more preferably at least 96%, 97%, 98% or 
99% identical, to any of the nucleotide sequences of the 
polynucleotides described above. 65 
As a practical matter, whether any particular vector or 
polynucleotide is at least 95%, 96%, 97%, 98% or 99% iden- 
tical to a nucleotide sequence according to the present inven-
tion, can be determined conventionally using known com-
puter programs such as the Bestfit program (Wisconsin 
Sequence Analysis Package, Version 8 for Unix, Genetics 
Computer Group, University Research Park 575 Science 
Drive, Madison, Wis. 53711). Bestfit uses the local homology 
algorithm of Smith and Waterman, Advances in Applied 
Mathematics 2:482-489 (1981), to find the best segment of 
homology between two sequences. When using Bestfit or any 
other sequence alignment program to determine whether a 
particular sequence is, for instance, 95% identical to a refer-
ence sequence according to the present invention, the param-
eters are set, of course, such that the percentage of identity is 
calculated over the full length of the reference nucleotide 
sequence and that gaps in homology of up to 5% of the total 
number of nucleotides in the reference sequence are allowed. 
Codon Optimization 
As used herein, the term "codon optimization" is defined as 
modifying a nucleic acid sequence for enhanced expression 
in the cells of the vertebrate of interest, e.g., human, by 
replacing at least one, more than one, or a significant number, 
of codons of the native sequence with codons that are more 
frequently or most frequently used in the genes of that verte-
brate. Various species exhibit particular bias for certain 
codons of a particular amino acid. 
In one aspect, the present invention relates to polynucle-
otide expression constructs or vectors, and host cells com-
prising nucleic acid fragments of codon-optimized coding 
regions which encode therapeutic polypeptides, and frag-
ments, variants, or derivatives thereof, and various methods 
of using the polynucleotide expression constructs, vectors, 
host cells to treat or prevent disease in a vertebrate. 
As used herein the term "codon-optimized coding region" 
means a nucleic acid coding region that has been adapted for 
expression in the cells of a given vertebrate by replacing at 
least one, ormore than one, or a significant number, of codons 
with one or more codons that are more frequently used in the 
genes of that vertebrate. 
Deviations in the nucleotide sequence that comprise the 
codons encoding the amino acids of any polypeptide chain 
allow for variations in the sequence coding for the gene. Since 
each codon consists of three nucleotides, and the nucleotides 
comprising DNA are restricted to four specific bases, there 
are 64 possible combinations of nucleotides, 61 of which 
encode amino acids (the remaining three codons encode sig-
nals ending translation). Many amino acids are designated by 
more than one codon. For example, the amino acids alanine 
and proline are coded for by four triplets, serine and arginine 
by six, whereas tryptophan and methionine are coded by just 
one triplet. This degeneracy allows for DNA base composi-
tion to vary over a wide range without altering the amino acid 
sequence of the proteins encoded by the DNA. 
Consensus Sequences 
The present invention is further directed to expressionplas-
mids that contain chimeric genes which express therapeutic 
fusion proteins with specific consensus sequences, and frag-
ments, derivatives and variants thereof. A "consensus 
sequence" is, e.g., an idealized sequence that represents the 
amino acids most often present at each position of two or 
more sequences which have been compared to each other. A 
consensus sequence is a theoretical representative amino acid 
sequence in which each amino acid is the one which occurs 
most frequently at that site in the different sequences which 
occur in nature. The term also refers to an actual sequence 
which approximates the theoretical consensus. A consensus 
sequence can be derived from sequences which have, e.g., 
shared functional or structural purposes. It can be defined by 
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aligning as many known examples of a particular structural or 	 skilled in the art in light of the foregoing disclosure. Accord- 
functional domain as possible to maximize the homology. A 
	
ingly, it is intended that all such alternatives, modifications, 
sequence is generally accepted as a consensus when each 	 and variations which fall within the spirit and the scope of the 
particular amino acid is reasonably predominant at its posi- 	 invention be embraced by the defined claims. 
tion, and most of the sequences which form the basis of the 5 	 The following examples are included for purposes of illus- 
comparison are related to the consensus by rather few substi- 	 tration only and are not intended to limit the scope of the 
tutions, e.g., from 0 to about 100 substitutions. In general, the 	 present invention, which is defined by the appended claims. It 
wild-type comparison sequences are at least about 50%,75%, 	 should be appreciated by those of skill in the art that the 
80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the 	 techniques disclosed in the examples which follow, represent 
consensus sequence. Accordingly, polypeptides of the inven-  io techniques discovered by the inventors to function well in the 
tion are about 50%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 	 practice of the invention, and thus can be considered to con- 
94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the 	 stitute preferred modes for its practice. However, those of 
consensus sequence. 	 skill in the art should, in light of the present disclosure, 
A "consensus amino acid" is an amino acid chosen to 	 appreciate that many changes can be made in the specific 
occupy a given position in the consensus protein. A system 15 embodiments which are disclosed and still obtain a like or 
which is organized to select consensus amino acids can be a 	 similar result without departing from the spirit and scope of 
computer program, or a combination of one or more computer 	 the invention. 
programs with "by hand" analysis and calculation. When a 	 Antibodies 
consensus amino acid is obtained for each position of the 	 Further embodiments of the invention include MucE and 
aligned amino acid sequences, then these consensus amino 20 A1gW monoclonal antibodies and methods of using MucE 
acids are "lined up" to obtain the amino acid sequence of the 	 and A1gW antibodies for the detection and diagnosis of 
consensus protein. 	 mucoid P. aeruginosa in biological specimens. The methods 
As mentioned above, modification and changes may be 	 comprise reacting a specimen suspected of containing 
made in the structure of the mucE coding region and still 	 mucoid P. aeruginosa with a MucE or A1gW monoclonal 
obtain a molecule having like or otherwise desirable charac-  25 antibody or fragment thereof, separating the specimen from 
teristics. As used herein, the term "biological functional 	 unbound antibody, and detecting the presence of immune 
equivalent" refers to such proteins. For example, certain 	 complexes formed between the monoclonal antibody and the 
amino acids may be substituted for other amino acids in a 	 MucE or A1gW protein, as compared to non-mucoid control 
protein structure without appreciable loss of interactive bind- 	 cells and therefrom determining the presence of mucoid P. 
ing capacity with structures such as, for example, antigen- 3o aeruginosa. Novel hybrid cell lines are also provided which 
binding regions of antibodies or binding sites on substrate 	 produce the monoclonal antibodies capable of specifically 
molecules. Since it is the interactive capacity and nature of a 	 binding to the MucE or A1gW protein expressed in P. aerugi- 
protein that defines that protein's biological functional activ- 	 nosa. When the monoclonal antibodies are labeled and com- 
ity, certain amino acid sequence substitutions can be made in 	 bined with a solubilizing reagent, a specific and rapid direct 
the DNA coding sequence and nevertheless obtain a protein 35 test for mucoid P. aeruginosa is achieved. 
with like or even counterveiling properties (e.g., antagonistic 	 The monoclonal antibodies of this invention can be pre- 
v. agonistic). It is thus contemplated by the inventors that 	 pared by immortalizing the expression of nucleic acid 
various changes may be made in the DNA sequence of mucE 	 sequences which code for antibodies specific for MucE or 
(or MucE proteins or peptides) without appreciable loss of 	 A1gW of P. aeruginosa. This may be accomplished by intro- 
their biological utility or activity. 	 4o ducing such sequences, typically cDNA encoding for the 
Polypeptides 	 antibody, into a host capable of cultivation and culture. The 
Further embodiments of the invention include polypep- 	 immortalized cell line may be a mammalian cell line that has 
tides, which comprise amino acid sequences at least 95% 
	
been transformed through oncogenesis, by transfection, 
identical, and more preferably at least 96%, 97%, 98% or 	 mutation, or the like. Such cells include myeloma lines, lym- 
99% identical, to any of the amino acid sequences of the 45 phoma lines, or other cell lines capable of supporting the 
polypeptides described above. 	 expression and secretion of the antibody in vitro. The anti- 
As a practical matter, whether any particular polypeptide is 	 body may be a naturally occurring immunoglobulin of a 
at least 95%, 96%, 97%, 98% or 99% identical to, for 	 mammal other than human, produced by transformation of a 
instance, the amino acid sequence shown in SEQ ID NOs:2 	 lymphocyte, by means of a virus or by fusion of the lympho- 
and 4 can be determined conventionally using known com-  50 cyte with a neoplastic cell, e.g., a myeloma, to produce a 
puter programs such as the Bestfit program (Wisconsin 	 hybrid cell line. Typically, the lymphoid cell will be obtained 
Sequence Analysis Package, Version 8 for Unix, Genetics 	 from an animal immunized against MucE or a fragment 
Computer Group, University Research Park 575 Science 	 thereof containing an epitopic site. 
Drive, Madison, Wis. 53711). Bestfit uses the local homology 	 Monoclonal antibody technology was pioneered by the 
algorithm of Smith and Waterman, Advances in Applied 55 work of Kohler and Milstein, Nature 256:495 (1975). Mono- 
Mathematics 2:482-489 (1981), to find the best segment of 	 clonal antibodies can now be produced in virtually unlimited 
homology between two sequences. When using Bestfit or any 	 quantities consistently and with a high degree of purity. These 
other sequence alignment program to determine whether a 	 qualities facilitate the reproducibility and standardization of 
particular sequence is, for instance, 95% identical to a refer- 	 performance of diagnostic tests which are required in hospi- 
ence sequence according to the present invention, the param-  60 tals and other clinical settings. 
eters are set, of course, such that the percentage of identity is 	 Immunization protocols are well known and can vary con- 
calculated over the full length of the reference amino acid 	 siderably yet remain effective. See Golding, Monoclonal 
sequence and that gaps in homology of up to 5% of the total 
	
Antibodies: Principles and Practice, (1983) which is incorpo- 
number of amino acids in the reference sequence are allowed. 	 rated herein by reference Immunogenic amounts of antigenic 
Even though the invention has been described with a cer-  65 MucE preparations are injected, generally at concentrations 
tain degree of particularity, it is evident that many alterna- 	 in the range of 1 ug to 20 mg/kg of host. Administration of the 
tives, modifications, and variations will be apparent to those 	 antigenic preparations may be one or a plurality of times, 
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usually at one to four week intervals Immunized animals are 	 antibody can bind. However, it is well known that indirect 
monitored for production of antibody to the desired antigens, 	 immunofluorescence is more prone to nonspecific staining 
the spleens are then removed and splenic B lymphocytes 	 than direct immunofluorescence, that is, staining which is not 
isolated and transformed or fused with a myeloma cell line. 	 due to the specific antigen-antibody interaction of interest 
The transformation or fusion can be carried out in conven-  5 (Johnson et al., in Handbook of Experimental Immunology, 
tional ways, the fusion technique being described in an exten- 	 D. M. Weir, ed., Blackwell Publications Oxford (1979); and 
sive number of patents, e.g., U.S. Pat. Nos. 4,172,124; 4,350, 	 Selected Methods in Cellular Immunology, Mishell et al., ed., 
683; 4,363,799; 4,381,292; and 4,423,147. See also Kennett 	 W. H. Freeman, San Francisco (1980)). In addition, the mul- 
et al., Monoclonal Antibodies (1980) and references therein. 	 tiple steps involved in performing the indirect tests makes 
The biological sample suspected of containing P. aerugi-  io them slow, laborintensive, and more susceptibleto technician 
nosa is combined withtheprimary antibody under conditions 	 error. 
conducive to immune complex formation. If the test is a 	 Various immunoassays known in the art can be used to 
one-step immunofluorescence assay, the primary antibody 	 detect binding of MucE or A1gW to antibodies, including but 
will be labeled. Typically, the specimen is first fixed or 	 not limited to, competitive and non-competitive assay sys- 
adhered to a glass slide by heat and/or ethanol treatment, 15 tems using techniques such as radioimmunoassays, ELISA 
although other fixatives or adherents are known by those 	 (enzyme linked immunosorbent assay), "sandwich" immu- 
skilled in the art. The specimen is then contacted with the 	 noassays, immunoradiometric assays, gel diffusion precipi- 
solubilizing agent for a sufficient period, usually from 1 to 30 	 tation reactions, immunodiffusion assays, in situ immunoas- 
minutes and more usually about 10 minutes, and the solubi- 	 says (using colloidal gold, enzyme or radioisotope labels, for 
lizer is then washed from the slide. Alternatively, as described 20 example), western blots, precipitation reactions, agglutina- 
above, the solubilizing agent and the primary antibody may 	 tion assays (e.g., gel agglutination assays, hemagglutination 
be combined and added as one step. The primary antibody 	 assays), complement fixation assays, immunofluorescence 
should be incubated with the specimen for approximately 30 	 assays, protein  assays, and immunoelectrophoresis assays, 
minutes at room temperature, although the conditions may be 	 etc. 
varied somewhat. The slide is rinsed to remove unbound 25 	 Kits can also be supplied for use with the subj ect antibodies 
antibody. If the primary antibody has been labeled with FITC, 	 in the detection of mucoid P. aeruginosa in specimens, 
the reacted sample may be viewed under a fluorescence 	 wherein the kits comprise compartments containing a MucE 
microscope equipped with standard fluorescein filters (exci- 	 and/or A1gW monoclonal antibody capable of reacting with 
tation=490 mu; emission-520 mu) and a 40x oil immersion 	 essentially all serotypes and immunotypes of P. aeruginosa, 
lens. The quantitation of fluorescence is based on visual 3o and labels and necessary reagents for providing a detectable 
observation of the brightness or relative contrast of the spe- 	 signal. Thus, the monoclonal antibody composition of the 
cifically stained antigen. Appropriate positive and negative 	 present invention may be provided, usually in a lyophilized 
controls make interpretation more accurate. A counterstain, 	 form, either alone or in conjunction with additional antibod- 
such as Evans blue, may be employed to more easily visualize 	 ies specific for other antigens of P. aeruginosa. The antibod- 
the fluorescent organisms. 	 35 ies, which may be conjugated to a label, are included in the 
The antibodies of the invention may be a chimeric antibody 	 kits with buffers, such as Tris, phosphate, carbonate, etc., 
or fragment thereof, a humanized antibody or fragment 	 stabilizers, biocides, inert proteins, e.g., bovine serum albu- 
thereof, a single chain antibody; or a Fab fragment. 	 min, or the like. Generally, these materials will be present in 
For use in diagnostic assays, the antibodies of the present 	 less than about 5% weight based on the amount of active 
invention may be directly labeled. A wide variety of labels 4o antibody, and usually present in a total amount of at least 
may be employed, such as radionuclides, fluorescence, 	 about 0.001% weight based on the antibody concentration. 
enzymes, enzyme substrates, enzyme cofactors, enzyme 	 Frequently, it will be desirable to include an inert extender or 
inhibitors, ligands (particularly haptens), etc. When unla- 	 excipient to dilute the active ingredients, where the excipient 
beled, the antibodies may find use in agglutination assays. In 	 may be present in from about 1% to 99% weight of the total 
addition, unlabeled antibodies can be used in combination 45 composition. Where a second antibody capable of binding to 
with other labeled antibodies (second antibodies) that are 	 the monoclonal antibody is employed, this will usually be 
reactive with the monoclonal antibody, such as antibodies 	 present in a separate vial. The second antibody may be con- 
specific for the immunoglobulin. Numerous types of immu- 	 jugated to a label and formulated in a manner analogous to the 
noassays are available and are well known to those skilled in 	 antibody formulations described above. 
the art. 	 50 Cystic Fibrosis (CF) Risk Assessment 
Immunofluorescence staining methods can be divided into 	 Further embodiments of the invention include methods for 
two categories, direct and indirect. In the direct staining 	 Cystic Fibrosis (CF) disease assessment in an individual 
method, a fluorophore is conjugated to an antibody (the "pri- 	 which comprise detecting the presence or absence of MucE 
mary antibody") which is capable of binding directly to the 	 and/orA1gW in a sample from an individual. Further embodi- 
cellular antigen of interest. In the indirect staining mode, the 55 ments include methods for Cystic Fibrosis (CF) disease 
primary antibody is not fluorescently labeled; rather, its bind- 	 assessment in an individual which comprise detecting the 
ing is visualized by the binding of a fluorescently labeled 	 presence or absence of MucE orA1gW antibodies in a sample 
second-step antibody, which second-step antibody is capable 	 from an individual. 
of binding to the primary antibody. Typically, the second-step 	 Additional embodiments include methods for treating P. 
antibody is an anti-immunoglobulin antibody. In some 6o aeruginosa biofilms in Cystic Fibrosis (CF) disease in an 
instances the second-step antibody is unlabeled and a third- 	 individual which comprise the steps of detecting the presence 
step antibody which is capable of binding the second-step 	 of MucE and/or A1gW in a sample from an individual; and 
antibody is fluorescently labeled. 	 selecting a therapy regimen for the individual based on the 
Indirect immunofluorescence is sometimes advantageous 	 presence of MucE and/or A1gW. The P. aeruginosa biofilms 
in that it can be more sensitive than direct immunofluores-  65 in Cystic Fibrosis (CF) disease are treated by the therapy 
cence because for each molecule of the primary antibody 	 regimen. Also contemplated are methods for treating P. 
which is bound, several molecules of the labeled second-step 	 aeruginosa biofilms in Cystic Fibrosis (CF) disease in an 
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individual which comprise the steps of detecting the presence 
of MucE and/or A1gW antibodies in a sample from an indi-
vidual; and selecting a therapy regimen for the individual 
based on the presence of MucE and/orA1gW antibodies. The 
P. aeruginosa biofilms in Cystic Fibrosis (CF) disease are 
treated by the therapy regimen. 
As used herein, "individual' is intended to refer to a 
human, including but not limited to, children and adults. One 
skilled in the art will recognize the various biological samples 
available for detecting the presence or absence of MucE or 
A1gW in an individual, any of which may be used herein. 
Samples include, but are not limited to, airway surface liquid, 
sputa, or combinations thereof, human blood, wound exu-
date, respiratory secretions, human tissues (e.g., lung) or a 
laboratory culture thereof, and urine. Moreover, one skilled in 
the art will recognize the various samples available for detect-
ing the presence or absence of MucE orA1gW antibodies in an 
individual, any of which may be used herein. Samples 
include, but are not limited to, airway surface liquid, sputa, or 
combinations thereof, human blood, wound exudate, respira-
tory secretions, human tissues (e.g., lung) or a laboratory 
culture thereof, urine, and other body fluids, or combinations 
thereof. 
As used herein, "assessment' is intended to refer to the 
prognosis, monitoring, delaying progression, delaying early 
death, staging, predicting progression, predicting response to 
therapy regimen, tailoring response to a therapy regimen, of 
Cystic Fibrosis disease based upon the presence or absence of 
MucE, A1gW, MucE antibodies, or A1gW antibodies in a 
biological sample. 
As used herein, "therapy regimen" is intended to refer to a 
procedure for delaying progression, or delaying early death 
associated with Cystic Fibrosis disease and/or Pseudomonas 
aeruginosa in a Cystic Fibrosis individual. In one embodi-
ment, the therapy regimen comprises administration of ago-
nists and/or antagonists of MucE and/or A1gW. In another 
embodiment, the therapy regimen comprises agonists and/or 
antagonists of Pseudomonas aeruginosa. 
One skilled in the art will appreciate the various known 
direct and/or indirect techniques for detecting the presence or 
absence of MucE or A1gW, any of which may be used herein. 
These techniques include, but are not limited to, amino acid 
sequencing, antibodies, Western blots, 2-dimensional gel 
electrophoresis, immunohistochemistry, autoradiography, or 
combinations thereof. 
All references cited in the Examples are incorporated 
herein by reference in their entireties. 
EXAMPLES 
Materials and Methods 
The following materials and methods apply generally to all 
the examples disclosed herein. Specific materials and meth-
ods are disclosed in each example, as necessary. 
The practice of the present invention will employ, unless 
otherwise indicated, conventional techniques of cell biology, 
cell culture, molecular biology (including PCR), vaccinol-
ogy, microbiology, recombinant DNA, and immunology, 
which are within the skill of the art. Such techniques are 
explained fully in the literature. See, for example, Molecular 
Cloning A Laboratory Manual, 2d Ed., Sambrook et al., ed., 
Cold Spring Harbor Laboratory Press (1989); DNA Cloning, 
Volumes I and II, D. N. Glover ed., (1985); Oligonucleotide 
Synthesis, M. J. Gait ed., (1984); Mullis et al. U.S. Pat. No. 
4,683,195; Nucleic Acid Hybridization, B. D. Flames & S. J. 
Higgins eds. (1984); Transcription And Translation, B. D. 
Flames & S. J. Higgins, eds. (1984); Freshney, R. L, Culture 
20 
OfAnimal Cells, Alan R. Liss, Inc. (1987); Immobilized Cells 
And Enzymes, IRL Press (1986); Perbal, B., A Practical 
Guide To Molecular Cloning (1984); the treatise, Methods In 
Enzymology, Academic Press, Inc., N.Y.; Gene Transfer Vec- 
5 tors For Mammalian Cells, J. H. Miller and M. P. Calos eds., 
Cold Spring Harbor Laboratory (1987); Methods In Enzymol-
ogy, Vols. 154 and 155, Wu et al. eds.; Immunochemical 
Methods In Cell And Molecular Biology, Mayer and Walker, 
eds., Academic Press, London, (1987); and in Ausubel et al., 
10 Current Protocols in Molecular Biology, John Wiley and 
Sons, Baltimore, Md. (1989). Each of the references cited in 
this paragraph is incorporated herein by reference in its 
entirety. 
15 Bacterial Strains, Plasmids, Transposons and Growth Condi-
tions 
P. aeruginosa strains were grown at 37° C. in Lennox broth 
(LB), on LB agar or Pseudomonas Isolation Agar (PIA, 
20 DIFCO) plates. When required, PIA plates were supple-
mented with carbenicillin, tetracycline, or gentamicin at a 
concentration of 300 ng/ml. E. coli strains were grown in LB 
broth, or LB agar supplemented with carbenicillin (100 
µg/ml), tetracycline (15 µg/ml), gentamicin (13 µg/ml), or 
25 kanamycin (40 µg/ml), when required. 
Transposon Mutagenesis 
A standard Pseudomonas conjugation protocol was fol-
lowed with the following modifications. E. coli SM10 Xpir 
30 carrying pFAC and P. aeruginosa strains were grown in 2 ml 
LB broth overnight at 37° C. and 42° C., respectively. The cell 
density of the cultures was measured by optical density at 600 
nm and adjusted to a ratio of 1:1, which was equivalent to 
8x10$ cells for matings. The mixed cultures were incubated 
35 
on LB plates for 6 h at 37° C. The cells were harvested and 
washed in LB broth. The final cell mixtures in a volume of 1 
ml were spread on 8 PIA plates (50 ml each) supplemented 
with gentamicin. The conjugal pairs were incubated at 37° C. 
40 for 24 h for selection and screening exconjugants with a 
mucoid colony morphology. Such mutants were isolated and 
purified a minimum of 3 times. Mutants were frozen in 10% 
skim milk in a —80° C. freezer. 
45 DNA Manipulations. 
Two steps ofpolymerase chain reaction (PCR)-based clon-
ing were used for general cloning purposes. First, the target 
genes were amplified by high-fidelity PCR using the appro- 
50 priate primer sets containing the built-in restriction sites fol-
lowed by cloning into pCR4-TOPO. The DNA fragments 
were digested by restriction enzymes, gel-purified, and trans-
ferred to the shuttle vector pUCP20. All recombinant plas-
mids were sequenced to verify the absence of mutations with 
55 M13 universal forward and reverse primers using an ABI 
3130 Genetic Analyzer at the Marshall University School of 
Medicine Genomics Core Facility. PCR reactions were per-
formed with MasterAmpTM Taq DNA Polymerase (Epicen- 
60 tre) in 50 l EasyStart PCR tubes (Molecular BioProducts) as 
previously described (Head, N. E., and H. Yu, Infect. Immun. 
72:133-44 (2004)). 
Inverse PCR (iPCR) 
65 	 The mariner transposon and its junction region in pFAC 
were sequenced. The sequence of the junction region includ- 
ing the inverted repeats in pFAC (SEQ ID NO:8) is as follows: 
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accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt cccattcgcc actcaaccaa gtcattctga 
gaatagtgta tgcggcgacc gagttgctct tgcccggcgt caatacggga taataccgcg ccacataaca 
ggttggctga taagtccccg gtctaacaaa gaaaaacaca tttttttgtg aaaattcgtt tttattattc aacatagttc 
ccttcaagag cgatacccct cgaattgacg cgtcaattct cgaattgaca taagcctgtt cggttcgtaa actgtaatgc 
aagtagcgta tgcgctcacg caactggtcc agaaccttga ccgaacgcag cggtggtaac ggcgcagtgg 
cggttttcat ggcttgttat gactgttttt ttgtacagtc tatgcctcgg gcatccaagc agcaagcgcg ttacgccgtg 
ggtcgatgtt tgatgttatg gagcagcaac gatgttacgc agcagcaacg atgttacgca gcagggcagt 
cgccctaaaa caaagttagg tggctcaagt atgggcatca ttcgcacatg taggctcggc cctgaccaag 
tcaaatccat gcgggctgct cttgatcttt tcggtcgtga gttcggagac gtagccacct actcccaaca 
tcagccggac tccgattacc tcgggaactt gctccgtagt aagacattca tcgcgcttgc tgccttcgac 
caagaagcgg ttgttggcgc tctcgcggct tacgttctgc ccaggtttga gcagccgcgt agtgagatct 
atatctatga tctcgcagtc tccggcgagc accggaggca gggcattgcc accgcgctca tcaatctcct 
caagcatgag gccaacgcgc ttggtgctta tgtgatctac gtgcaagcag attacggtga cgatcccgca 
gtggctctct atacaaagtt gggcatacgg gaagaagtga tgcactttga tatcgaccca agtaccgcca 
cctaacaatt cgttcaagcc gagatcggct tcccggccga cgcgtcctcg gtaccgggcc ccccctcgag 
gtcgacggta tcgataagct tgatatcgaa ttcctgcagc ccgggaatca tttgaaggtt ggtactatat aaaaataata 
tgcatttaat actagcgacg ccatctatgt gtcagaccgg ggacttatca gccaacctgt tagcagaact 
ttaaaagtgc tcatcattgg aaaaaggctg cgcaactgtt gggaagggcg atcggtgcgg gcctcttcgc 
tattacgcca gctggcgaaa gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca 
gtcacgacgt tgtaaaacga cggccagtga gcgcgcgtaa tacactcact atagggcgaa ttggaggatc 
cggtctaaca aagaaaacac attttttgtg aaa 
35 
A multiple cloning site (MCS) was identified immediately min. The protein assay was performed using the Bio-Rad D, 
outside the 3' end of the gentamicin cassette within the trans- Protein Assay kit. The range for protein standard (bovine 
poson. To map the insertion site, an iPCR protocol was devel- serum albumin) curve was from 0.2 to 1.2 mg/ml. 
oped to utilize this convenient MCS. Pseudomonas genomic 40 (3-Galactosidase Activity Assay 
DNA was purified using a QIAamp genomic DNA kit. The The assay was based on the method as originally described 
DNA concentration was measured using the NanoDrop® by Miller (In Experiments in Molecular Genetics, J. H. 
ND-1000 spectrophotometer (NanoDrop Technologies). Two Miller, ed., Cold Spring Harbor Laboratory, Cold Spring Har- 
µg DNA was digested by restriction enzymes Sall or PstI at bor, N.Y. (1972), pp. 352-355) with the following modifica- 
37° C. overnight followed by gel purification. The frag- 45 tion. The cells of NHl-3 were grown on PIA plates in tripli- 
mented DNA was ligated to form the circularly closed DNA catefor24 hat37° C. The cells wereharvestedinPBS andcell 
using the Fast-LinkTM DNA ligation kit (Epicentre). A vol- density was measured by OD 600 . Samples were assayed after 
ume of 1 µl ligated DNA was used as template for PCR using SDS/chloroform permeabilization of the cells. 
GM50UT and GM30UT according to the condition as fol- Alkaline PhosphataseA-Fusion Assay 
lows, 94° C. for 1 min, 34 cycles consisting of 94° C. for 1 	 50 The entire open reading frame and different portion of 
min, 58° C. for 2 min, and 72° C. for 2 min, and a final mucE were translationally fused with the E. coli phoA gene 
extension step consisting of 72° C. for 8 min. After PCR, the with deletion of the sequence encoding the N-terminal signal 
products were analyzed on a I% agarose gel. The PCR prod- sequence. These mucE-phoA fusions were cloned into 
ucts were purified using the QIAquick PCR purification kits pUCP20 vector for alkaline phosphatase A-fusion assay as 
and sequenced using GM50UT as described above. 	 55 previously described (Lewenza, S. et al., Genome Res. 
Alginate and Protein Assays 15:321-329 (2005); Manoil, C. et al., J. Bacterol. 172:515- 
The alginate assay was based on a previously published 518 (1990)) andthe transformants wereplatedonthe LB plate 
method (Knutson, C. A., and A. Jeans, Anal. Biochem. containing 40 µg/ml BCIP. The construct pUCP20-phoA 
24:470-481 (1968)) with the following modifications. P. expressing full-length PhoA was used as a positive control 
aeruginosa and mutants were grown on 50 ml PIA plates in 6o and the pUCP20-phoA expressing the truncated PhoA with- 
triplicate for a period of 72 h. At various time points, bacterial out N-terminal signal leader sequence as a negative control. 
growth was removed from plates and re-suspended in 40 ml RNA Isolation and RT-PCR 
phosphate-buffered saline (PBS; pH 7.4). The optical density P. aeruginosa strains PAO1, VE2 and VE3 were grown on 
at 600 mn (OD 600) was recorded. The alginate standard curve 50 ml PIA plates for 24 h at 37° C. The cells were harvested 
was made using D-mannuronic acid lactone (Sigma) in the 65 in 40 ml PBS and re-suspended based on OD 600 to produce a 
range of 0-100 µg/ml. To measure the protein concentration, cell population of 109 to 10 10 . Total RNA was isolated using 
the cells in PBS were lysed in 1:1 ratio with 1 M NaOH for 15 a RiboPureTM-Bacteria Kit (Ambion) followed by DNase 
US 8,399,649 B2 
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treatment as supplied. The quality of RNA was evaluated on 
an Agilent 2100 bioanalyzer. RT-PCR was performed using a 
One-Step RT-PCR kit (Qiagen). One µg bacterial RNA was 
reverse-transcribed into cDNA at 50° C. for 30 min followed 
by PCR amplification: 94° C. for 15 min, 34 cycles consisting 
of 94° C. for 1 min, 58° C. for 2 min, and 72° C. for 2 min. The 
PCR products were analyzed on 1% agarose gel, and the 
intensity of bands was analyzed on a Typhoon 8600 Variable 
Mode Imager (Molecular Dynamics) withthe ImageQuant (v. 
5.2) Software. 
Monoclonal Antibodies 
The A1gU and MucB monoclonal antibodies used in the 
Examples are from previously published sources (Boucher et 
al., J. Bacteriol. 178:511-523 (1996); Schurr et al., J. Bacte-
riol. 178:4997-5004 (1996)) with a low level of cross-reac-
tivity. The specificities of these antibodies are appropriate 
because the a1gU and mucB negative strains failed to display 
the respective A1gU and MucB proteins (FIG. 8). Further-
more, two non-specific proteins of 50 kDa and 75 kDa from 
MucB and A1gU blots respectively were used as convenient 
internal controls to normalize the protein levels. 
Southern Hybridization 
A 754 by PCR product was amplified from accl o 
pUCP30T using GM-F and GM-R primers, which was puri-
fied via gel extraction and labeled with digoxygenin as 
described by the manufacturer (Roche Molecular Biochemi-
cals). Agarose gels were soaked in 0.25 N HCl for 30 min, 
rinsed in H2O, soaked in 1.5 M NaCI/0.5 M NaOH for 30 min 
and 1.5 M NaCl/0.5 M Tris-Cl, pH 8.0 for 30 min. A blotting 
apparatus (BIO-RAD Vacuum Blotter) was used with a filter 
paper wick, a Hybond-N+ membrane (Amersham Pharmacia 
Biotech), and transferred with l OxSSC transfer buffer for 2 h. 
After transfer, the membrane was rinsed in transfer buffer and 
UV cro ss-linked. Hybridization was done using the DIG High 
Prime DNA Labeling and Detection Starter Kit II (Roche 
Applied Science) and labeled probe described above. 
Western Blot Analysis. 
Forty µg of total protein was prepared by bead-beating 3x 
for 1 min with 5 min intervals on ice. The proteins were mixed 
with 2xSDS-PAGE sample buffer. A Precision Plus Protein 
Standard (Bio-Rad) was used as molecular mass ranging 
from 10 to 250 kD. Protein and standard were loaded into a 
Criterion pre-cast gel of linear gradient (10-15% Tris-HCI 
gel) (Bio-Rad) and was run in a Criterion Cell (Bio-Rad) at 
60V for 4 h. The transfer onto a PVDF membrane was done in 
a Criterion Blotter (Bio-Rad) with CAPS buffer at 50V for 1 
h. Primary antibodies were obtained using standard tech-
niques. Horseradish Peroxidase-labeled secondary antibod-
ies, goat anti-mouse IgG (H+L) and goat anti-rabbit IgG 
(H+L), were obtained from Peirce Biotechnologies and 
Kirkegaard & Perry Laboratories, respectively. Primary anti-
bodies were diluted 1:1000 and secondary antibodies 1:5000 
in TBS/Tween before application. ECL Western Blotting 
Detection System (Amersham Biosciences) was used to 
detect the protein of interest. X-ray film was exposed, and 
developed on an Alphatek AX390SE developer. The protein 
intensity was analyzed using a ChemiDoc XRS system (Bio-
Rad) and Quantity One software (Bio-Rad). These results 
were normalized against an internal protein within each 
sample. The relative expression level for each protein was 
then compared. 
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Example 1 
15 
Mariner-Based Transposon Mutagenesis Approach to 
Identify Mucoid Mutants in P. aeruginosa 
20 	 To investigate alginate regulation in P. aeruginosa, the 
versatile Tcl/mariner himarl transposon carried on pFAC 
(GenBank Accession number DQ366300), a Pseudomonas 
suicide plasmid, was used to mutagenize the non-mucoid 
strains of P. aeruginosa coupled with a genetic screen for 
f 25 mucoid mutants. 
The transposition efficiency of this transposon is high and 
has been shown to cause high-density insertions in P. aerugi-
nosa (Wong, S. M. and Mekalanos, J. 7., Proc Nad Acad Sci 
US 97:10191-10196 (2000)). Moreover, this transposon can 
30 knockout, knockdown or induce expression of the target gene 
depending on the nature of its insertion. The mariner trans-
poson himarl can jump onto the TA dinucleotides in non-
essential genes. These sites are abundant in the genomes of P. 
aeruginosa strains. Based on the two completed genomes, 
35 there are 94,404 and 100,229 such sites in PAOI (Stover et al., 
Nature 406:959-964 (2000)) and PA14 respectively, which 
gives rise to 17-18 per ORE. In addition, pFAC can cause 
increased or reduced expression of the target gene by insert- 
40 
ing into the intergenic region. 
Four non-mucoid strains were subject to transposon 
mutagenesis. Only three regions were targeted in this back-
ground: i) 6x in the a1gU promoter region, ii)1 x in mucA, and 
iii) 3 x in the intergenic region between a1gU and mucA (Table 
45 1). The a1gU promoter mutants caused increased expression 
of A1gU while the mucA and the a1gU-mucA intergenic 
mutants affected the activity of A1gU. These results indicate 
that A1gU has a key role in alginate overproduction in 
PAO579NM. 
50 	 A total of 370,000 clones were screened from 13 conjuga- 
tions (Table 1). Eighty-five mucoid mutants were isolated 
with 90% carrying single insertions as verified by Southern 
blot analysis (data not shown). To map the site of transposon 
insertions, iPCR was performed with 90% of PCR reactions 
55 producing single products. The iPCR results displayed a 
100% correlation with Southern blots. The iPCR products 
were used as templates for DNA sequencing. Seventy-eight 
mutants with single insertions were mapped. We next created 
the criteria of differentiating the independent mutational 
60 events. Independent and non-sibling mutants were defined as 
those carrying a transposon at different sites, or at the same 
sites but were obtained through different matings. Using 
these criteria, a collection of 45 independent mucoid mutants 
was obtained and classified in 9 different functional groups 
65 (Table 1). The mutagenesis approach used here was at a 
saturating level because multiple insertions at the same sites 
were repeatedly targeted (FIG. 5). 
Statistical Analysis 
Analysis of alginate production (3-galactosidase activity 
was done with one-way analysis of variance (ANOVA) fol- 
5 lowed by pairwise multiple comparisons with Holm-Sidak 
method. Analysis of normalized protein intensity was carried 
out with the means of each group in comparison with that of 
PAOI using t test assuming unequal variance or ANOVA if 
multiple groups were compared. All analyses were performed 
10 with SigmaStat (v. 3.1, Systat Software) and SigmaPlot (v. 
9.0, Systat Software) software. 
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TABLE I 
Transposon mutagenesis analysis of alginate regulators in four non-mucoid strains of 
P. aeruginosa  
PAOI PA0579NM 	 PA14 FRD2 Sum 	 Freq 
# matings 4 3 	 3 3 13 
# mutants screened 81,280 88,800 	 126,000 75,000 371,080 
# mucoid obtained 3218 31 	 4 85 
# independent mutants 21 10 	 11 3 45 
mutation freq 3.9 x 10 -4 2.0 x 10 -4 	 2.5 x 10-4 5.3 x 10-s 
Induction°  
PA0762-algUpromoter 5 (23.8) 6 (60.0) 	 8 (72.7) 3 (100.0) 22 49 
PA4033-mucE 1 (4.8) 1 (9.1) 2 4 
PA4082-cupB5 1 (4.8) 1 2 
Knockdown' 
PA0762-algU 2 (9.5) 3 (30.0) 5 11 
PA0973-oprL 1 (4.8) 1 2 
Knockout`  
PA0763-mucA 1 (10.0) 1 2 
PA0764-mucB 1 (4.8) 1 (9.1) 2 4 
PA0766-mucD 9(42.9) 1 (9.1) 10 22 
PA5484-king 1 (4.8) 1 2 
,,b 
'The number ofmutants obtained from each strain off. aeruginosa is shown. Number inside a bracket denotes the 
percentage of a mutation in the total number of mutants within a strain. 
25 
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Similar to another himarl transposon vector of the same 
lineage but constructed for M. tuberculosis studies (Rubin, E. 
7., et al., Proc Natl Acad Sci USA 96:1645-1650 (1999)), the 
transposon end in pFAC has no termination sequences. There-
fore, three types of mutations can be caused by the transposon 
in thi s vector depending on how and where it is inserted on the 
genome. As shown in Table 1, when inserted in the a1gU, 
mucE or cupB5 promoter region, the transposon used its d' 
promoter (Pam) (Wohlleben, W., et al., Mol Lien Genet. 217: 
202-208 (1989)) to direct the expression of the downstream 
genes. Reduced (knockdown) expression occurred when the 
transposon was inserted in the intergenic region of algUmucA 
or immediately downstream of oprL with P, m in the opposite 
direction with regard to the upstream algU or oprL. When the 
transposon was within the coding sequences, this produced 
stop codons away from insertion sites due to frameshift muta-
tions, producing gene knockouts for mucA, mucB, mucD and 
kinB. 
The mucoid phenotype poises a great demand for energy 
from the cells. The amount of alginate in mucoid mutants was 
initially lower than that of the wild-type strain PAOI (FIG. 
6A-8A), suggesting that mucoid mutants may grow slower 
than the non-mucoid counterparts to compensate for the 
energy demand. 
Example 2 
The Majority of Insertions are within 
algUmucABCD and Result in Upregulation of A1gU 
While all pFAC insertions were within five clusters (data 
not shown), the most frequent sites (49%) were in the algU 
promoters with the transposons situated in the induction con-
figuration. Since the algUmucABC genes are co-transcribed 
(DeVries, C. A. & Ohman, D. E., JBacteriol 176:6677-6687 
(1994); Firoved, A. M. & Deretic, V., JBacteriol 185:1071-
1081 (2003)), the levels ofAlgU and MucB were measured in 
these mutants. VEl, one of the representative promoter 
mutants as shown in FIG. 5, was grown on PIA plates for 
quantification of alginate and the protein levels of A1gU and 
MucB. 
As the results show, compared to PAOL VEl produced 
increased amounts of alginate from 24 to 72 h in concurrence 
with increased levels ofAlgU and MucB (FIG. 6). The level 
30 
of A1gU was higher than that of MucB (P -0.005). A1gU and 
MucB reached the steady-state level at 4 h and remained so 
for the rest of the time points. The algU mutants in 
PA0579NM, PA14 and FRD2 were mucoid and displayed the 
same trend as VEI regarding alginate production and protein 
35 levels ofA1gU and MucB. These results indicate that the algU 
promoter mutations were gain-of-function and associated 
with an elevated level of A1gU. 
Twenty eight percent of mucoid mutants had insertions in 
the coding regions of mucA, mucB and mucD (Table 1). The 
40 A1g'phenotypeof the mucD - mutants (DR8,VE19,VE1423 
and VE12) was complemented to Alg by mucD or mucBCD 
in trans. VE3 and VI, the equivalent of a triple knockout of 
mucA-B-C- in PAOI and PA0579NM respectively, were 
complemented to Alg by mucA, but not by mucBC or 
45 mucBCD, in trans. The Alg' phenotype in mucB - mutants of 
PAOI (VE8) and PA14 (DRI) was complemented to Alg by 
mucB, mucBC and mucBCD, in trans. These results suggest 
that the insertions in mucA, mucB and mucD are loss-of- 
50 
function (null) mutations. 
Example 3 
mucE and cupB5 Encode Two Novel Positive 
55 	 Regulators of Alginate 
Alginate is regulated by a signal transduction pathway. 
While ample information is available on the interaction 
between the sigma factor A1gU and trans-inner membrane 
60 anti-sigma factor MucA, it is unclear what and how periplas- 
mic signals activate the A1gU pathway leading to alginate 
overproduction. MucE and CupB5 identified here are two 
candidates for such signals. VE2 and DR4 had two identical 
insertions 16 bps upstream of ATG of PA4033 in PAOI and 
65 PA 14, respectively (data not shown). The transposon in both 
mutants was in the induction configuration (Table 1). PA4033 
belongs to a class of unclassified open reading frames (ORE) 
US 8,399,649 B2 
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in the annotated genome of PAO1, and encodes a hypothetical 	
-continued  
peptide (89 aa) with a predicted molecular mass of 9.5 kDa. 	 CAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTT 
The protein has a leader sequence of 36 as with the mature 	
ACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGA 
MucE protein exported to periplasm. In E. coli, the o-E path- 
way is activated via a Similar Signal transduction system in 5 CTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGG 
which an outer membrane porin, OmpC Serves as an inducing 	
GGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAAC 
signal. The carboxy-terminal signal of MucE (WVF) has a 
three consensus as sequence as does OmpC (YQF) (Walsh, N. 	 TGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAG 
P., et al., Cell 113:61-71 (2003)) and CupBS (NIW). 
The results Show that alginate production in VE2 was 10 GGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGA 
increased after 24 h (FIG. 7A) in association with the 	 GAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGT 
increased levels of A1gU and MucB compared with PAO1 at 
all time points (FIG. 7A vs. FIG. 6B). The wild-type and 	 CCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT 
mucoid mutation alleles of PA4033 plus its upstream region 15 CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTT 
were cloned into pUCP20. The resultant plasmid was named 
pUCP20-Gm-MULE (5622 bp) and has the following nucle- 	 TTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATAAGCTAGCTTAT 
otide sequence(SEQ ID NO: 9): 	 CGGCCAGCCTCGCAGAGCAGGATTCCCGTTGAGCACCGCCAGGTGCG 
GACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCAT 
GATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGC 
GCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCC 
GCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG 
GAAGGATATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTG 
CGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT 
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACT 
GGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACG 
TTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTAT 
CCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATT 
CTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTAC 
GGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGT 
GATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAG 
GAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGA 
TCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGA 
CACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACT 
GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGA 
GGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGG 
CTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA 
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATC 
TACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCG 
CTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGT 
TTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAA 
GGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT 
AATAAGGGACAGTGAAGAAGGAACACCCGCTCGCGGGTGGGCCTACTT 
20 
CACCTATCCTGCCCGGCTGACGCCGTTGGATACACCAAGGAAAGTCTAC 
ACGAACCCTTTGGCAAAATCCTGTATATCGTGCGAAAAAGGATGGATATA 
CCGAAAAAATCGCTATAATGACCCCGAAGCAGGGTTATGCAGCGGAAAG 
25 
TATACCTTAAGGAATCCCCATGTTCTTTCCTGCGTTATCCCCTGATTCT 
GCGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCG 
CACGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCG 
30 
CCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGC 
AGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAAC 
GCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACAC 
35 
TTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT 
ATCACCAGGAAACAGCTATGACCATGATTACGAATTCGAGCTCGGTA 
CCCCTAGCTGATTCCAAATAGCCATTAAGCGGGACGAAGAGCCCGT 
40 GAGCCAGCGCCAGCCTGACCTAACAGGTTGGCTGATAAGTCCCCGG 
TCTAACAAAGAAAAACACATTTTTTTGTGAAAATTCGTTTTTATTATTCA 
ACATAGTTCCCTTCAAGAGCGATACCCCTCGAATTGACGCGTCAATT 
45 CTCGAATTGACATAAGCCTGTTCGGTTCGTAAACTGTAATGCAAGTAG 
CGTATGCGCTCACGCAACTGGTCCAGAACCTTGACCGAACGCAGCG 
GTGGTAACGGCGCAGTGGCGGTTTTCATGGCTTGTTATGACTGTTTTTT 
50 TGTACAGTCTATGCCTCGGGCATCCAAGCAGCAAGCGCGTTACGCC 
GTGGGTCGATGTTTGATGTTATGGAGCAGCAACGATGTTACGCAGCAG 
CAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGGTG 
55 GCTCAAGTATGGGCATCATTCGCACATGTAGGCTCGGCCCTGACCAA 
GTCAAATCCATGCGGGCTGCTCTTGATCTTTTCGGTCGTGAGTTCGGA 
GACGTAGCCACCTACTCCCAACATCAGCCGGACTCCGATTACCTCG 
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATC 
GGAACTTGCTCCGTAGTAAGACATTCATCGCGCTTGCTGCCTTCGAC 
AAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGC 	 60 
CAAGAAGCGGTTGTTGGCGCTCTCGCGGCTTACGTTCTGCCCAGGTT 
AAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAA 
TGAGCAGCCGCGTAGTGAGATCTATATCTATGATCTCGCAGTCTCCG 
GAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCA 
GCGAGCACCGGAGGCAGGGCATTGCCACCGCGCTCATCAATCTCC 
GATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTT 	 65 
TCAAGCATGAGGCCAACGCGCTTGGTGCTTATGTGATCTACGTGCAA 
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GCAGATTACGGTGACGATCCCGCAGTGGCTCTCTATACAAAGTTGG 
GCATACGGGAAGAAGTGATGCACTTTGATATCGACCCAAGTACCGC 
CACCTAACAATTCGTTCAAGCCGAGATCGGCTTCCCGGCCGACGC 
GTCCTCGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAG 
CTTGATATCGAATTCCTGCAGCCCGGGAATCATTTGAAGGTTGGTAC 
TATATAAAAATAATATGCATTTAATACTAGCGACGCCATCTATGTGTC 
AGACCGGGGACTTATCAGCCAACCTGTTATCAAGGAGTCGTAGCCAT 
GGGTTTCCGGCCAGTTAGCCAACGTTTGCGTGACATCAACCTGCAGG 
CCCTCGGCAAGTTTTCCTGCCTTGCCCTGGTCCTCGGCCTGGAATCG 
GTAAGCCATCCGGCCGGCCCGGTCCAGGCCCCCTCGTTCAGCCAGG 
GCACCGCCAGCCCGTCCTTCGCTACTCCGCTCGGCCTCGACGGCCC 
GGCCCGCGCCAGGGCCGAGATGTGGAACGTCGGCCTGTCCGGCGC 
CGTCAGCGTGCGTGACGAGTTGCGCTGGGTGTTTTGAACGCGAAGCTT 
AGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGG 
CCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAAC 
TTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCG 
AAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAAA 
GGCAGGCCGGGCCGTGGTGGCCACGGCCTCTAGGCCAGATCCAGCG 
GCATCTGGGTTAGTCGAGCGCGGGCCGCTTCCCATGTCTCACCAGGG 
CGAGCCTGTTTCGCGATCTCAGCATCTGAAATCTTCCCGGCCTTGCGC 
TTCGCTGGGGCCTTACCCACCGCCTTGGCGGGCTTCTTCGGTCCAAAA 
CTGAACAACAGATGTGTGACCTTGCGCCCGGTCTTTCGCTGCGCCCAC 
TCCACCTGTAGCGGGCTGTGCTCGTTGATCTGCGTCACGGCTGGATCAA 
GCACTCGCAACTTGAAGTCCTTGATCGAGGGATACCGGCCTTCCAGTTG 
AAACCACTTTCGCAGCTGGTCAATTTCTATTTCGCGCTGGCCGATGCTGT 
CCCATTGCATGAGCAGCTCGTAAAGCCTGATCGCGTGGGTGCTGTCCAT 
CTTGGCCACGTCAGCCAAGGCGTATTTGGTGAACTGTTTGGTGAGTTCCG 
TCAGGTACGGCAGCATGTCTTTGGTGAACCTGAGTTCTACACGGCCCTC 
ACCCTCCCGGTAGATGATTGTTTGCACCCAGCCGGTAATCATCACACTC 
GGTCTTTTCCCCTTGCCATTGGGCTCTTGGGTTAACCGGACTTCCCGCCG 
TTTCAGGCGCAGGGCCGCTTCTTTGAGCTGGTTGTAGGAAGATTCGATAG 
GGACACCCGCCATCGTCGCTATGTCCTCCGCCGTCACTGAATACATCAC 
TTCATCGGTGACAGGCTCGCTCCTCTTCACCTGGCTAATACAGGCCAGAA 
CGATCCGCTGTTCCTGAACACTGAGGCGATACGCGGCCTCGACCAGGG 
CATTGCTTTTGTAAACCATTGGGGGTGAGGCCACGTTCGACATTCCTTG 
TGTATAAGGGGACACTGTATCTGCGTCCCACAATACAACAAATCCGTC 
CCTTTACAACAACAAATCCGTCCCTTCTTAACAACAAATCCGTCCCTT 
AATGGCAACAAATCCGTCCCTTTTTAAACTCTACAGGCCACGGATTAC 
GTGGCCTGTAGACGTCCTAAAAGGTTTAAAAGGGAAAAGGAAGAAAAG 
GGTGGAAACGCAAAAAACGCACCACTACGTGGCCCCGTTGGGGCCG 
30 
-continued 
CATTTGTGCCCCTGAAGGGGCGGGGGAGGCGTCTGGGCAATCCCCGT 
TTTACCAGTCCCCTATCGCCGCCTGAGAGGGCGCAGGAAGCGAGTAA 
5 TCAGGGTATCGAGGCGGATTCACCCTTGGCGTCCAACCAGCGGCACC 
AGCGGCGCCTGAGAGGTATGGTGCACTCTCAGTACAATCTGCTCTGAT 
GCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGC 
10 GCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGT 
GACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCG 
AAACGCGCGA 
15 
	
The PA4033 (VE2) but not wild-type PA4033 allele caused 
mucoid conversion in PAOI and PA14 in association with an 
elevated level ofA1gU in comparison with the parent (data not 
shown). Because the insertional mutation was dominant over 
the wild-type allele, we suspected that VE2 was overproduc-
ing the mucE product. Using RT-PCR, we determined that the 
20 levels of mucE and a1gU mRNA were 7-fold and 1.2-fold 
higher in VE2 (PAO1 mucE"') than in PAO1 respectively 
(FIG. 713). Because of the positive effect on alginate regula-
tion, PA4033 was named mucE. 
We also tested whether introduction of pUCP20-Gm'- 
25 mucE or pUCP20-P,m -mucE plasmids could cause mucoid 
conversion in other non-mucoid P. aeruginosa strains. We 
observed the emergence of a mucoid phenotype in the envi-
ronmental isolate ERC-1 and non-mucoid clinical CF isolates 
including CF149 (Head, N. H. et al., Infect. Immun. 72:133- 
30 144 (2004)) and early colonizing strains (C0746C, C0126C, 
C0686C, C1207C, C3715C, C4009C, C7406C and C8403C) 
(data not shown). Therefore, the extracytoplasmic stress sig-
nals may play an important role in the initial lung colonization 
and mucoid conversion of P. aeruginosa. 
35 	 Induction of MucE initiates a regulatory cascade causing 
an increased level of A1gU. It appears that induction of A1gU 
is the major pathway that governs alginate overproduction. 
The mutants that operate via this pathway include VE I (algU 
promoter mutants), VE2 (mucE +Oe) and VE22 (cupB5 +Oe) 
and VE13 (kinB-). One common feature is that an elevated 
40 level of MucB did not seem to match with that ofA1gU (FIGS. 
6A-8A). As the algUmucA-D genes are an operon, this sug-
gests that the level of MucA in these mutants may not be the 
same as that of A1gU. The excess A1gU could escape from the 
antagonistic interaction with MucA, thus causing mucoid 
45 conversion. 
Another mutant, VE22, which had a dominant effect on 
alginate overproduction, carried an insertion at 96 by before 
ATG of cupB5 (PA4082) (Table 1). The cupB5 gene encodes 
a probable adhesive protein (1,018 aa) with a predicted 
50 molecular mass of 100 kDa. This protein has a signal peptide 
of 53 aa, suggesting that the mature protein is bound for the 
extracellular milieu. The protein shares consensus motifs of 
the filamentous hemagglutinin and IgAl -specific metalloen-
dopeptidases (GLUG) at the N- and C-terminus, respectively. 
55 The cupB5 gene sits within a genetic cluster encoding fim-
brial subunits and CupB5, which have been proposed to be the 
chaperone/usher pathway involved in biofilm formation (Val-
let, I., et al., Proc NatlAcad Sci USA 98:6911-6916 (2001)). 
Induction of cupB5 in VE22 caused upregulation ofA1gU and 
60 MucB (FIG. 813). 
Example 4 
KinB is a Negative Regulator of Alginate in PAO1 
65 
As a sensor-kinase, KinB is responsible for responding to 
some environmental signals and phosphorylating a response 
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regulator, A1gB, via signal transduction. One mutant, VE13, The oprL gene encodes a homolog of the peptidoglycan asso- 
displayed a stable mucoid phenotype (Table 1). The mutation ciated lipoprotein precursor (168 aa) with a predicted 
of VE13 was mapped to 788 bps after ATG of kinB. This molecular mass of 18 kDa. OprL has a leader sequence of 24 
insertion caused a frameshift mutation with a stop codon as which probably directs the mature protein to the outer 
created at 54 bps after the insertion site. To ensure that inac- 5 membrane. Reduced expression of oprL in VE24 caused 
tivation of kinB was causal for the phenotype, PAOI kinBwas 
cloned into pUCP20. Introduction of wild-type kinB in trans mucoid conversion in PAOI, and was associated with a 
into VE13 reversed the phenotype from Alg to Alg . Algi- reduced level of A1gU and MucB (FIG. 8B). 
nate production in VE13 was significantly higher than that in 
PAOI, which was associated with the increased amount of 
A1gU (P-0.005) while the level of MucB remained 10 Example 6 
unchanged (P-0.07) compared with PAOI (FIGS. 8A and 
6A). 
The results show that the kinase activity inhibits overpro- Nonmucoid Revertants in A1gU-Hyperactive 
duction of alginate, thereby formally establishing the role of Mutants were Caused by Suppressor Mutations 
KinB as a negative regulator of alginate. A1gB is a well- 15 	 Inactivating a1gU known transcriptional activator for alginate biosynthesis. 
VE13 is a kinB null mutant of PAOI, and theAlg' phenotype 
has been complemented to Alg by pUCP-kinB in trans. 
Inactivation of kinB in PAOI increased the levels of A1gU Eleven percent of insertions were in the intergenic region 
(FIG. 8A), suggestingthatKinB may inhibittheexpressionof 20 between a1gU and mucA in the knockdown configuration 
a1gU via an A1gB-independent fashion. Alternatively, since (Table 1). The mutants of this category were hyper mucoid. 
A1gB in VE13 is probably in an un-phosphorylated or under- The level ofA1gU in VE3 was slightly reduced compared with 
phosphorylated state, it is possible that this form of A1gB that in PAOI (FIG. 813). The abundance of a1gU mRNA in 
serves as the transcriptional activator for alginate. VE3 was 84% of that in PAOI based on RT-PCR (FIG. 713). 
Example 5 25 Four random spontaneous non-mucoid revertants of VE3, 
PAOI-VE3-NMI-4, were isolated (GenBank accession num- 
Reduced Expression of oprL Causes Mucoid hers DQ352563, DQ352564, DQ352565, and DQ352566). 
Conversion in PAOI Sequencing the a1gU gene in VE3-NMI, -NM2, -NM3 and 
-NM4 revealed that all carried a completely inactivated a1gU 
One mutant, VE24, had an insertion at the stop codon 30 gene due to tandem duplications or a nonsense mutation. The 
(TAA) of oprL (PA0973) in the knockdown configuration. nucleotide sequences of these four a1gU mutants are: 
VE3-NM1 (SEQ ID NO: 10): 
cgattcgctg ggacgctcga agctcctcca ggttcgaaga ggagctttca tgctaaccca ggaacaggat 
cagcaactgg ttgaacgggt acagcgcgga gacaagcggg ctttcgatct gctggtactg aaataccagc 
acaagatact gggattgatc gtgcggttcg tgcacgacgc ccaggaagcc caggacgtag cgcaggaagc 
cttcatcaag gcataccgtg cgctcggcaa tttccgcggc gatagtgctt tttatacctg gctgtatcgg atcgccatca 
acaccgcgaa gaaccacctg gtcgctcgcg ggcgtcggcc accggacagc gatgtgaccg cagaggatgc 
ggagttcttc gagggcgacc acgccctgaa ggacatcgag tcgccggaac gggcgatgtt gcgggatgag 
atcgaggcca ccgtgcacca gaccatccag cagttgcccg aggatttgcg cacggccctg accctgcgcg 
agttcgaagg tttgagttac gaagatatcg ccaccgtgat gcagtgtccg gtggggacgg tgtccggtgg 
ggacggtacg gtcgcggatc ttccgcgctc gtgaagcaat cgacaaagct ctgcagcctt tgttgcgaga 
agcctgacac agcggcaaat gccaagagag gtta 
VE3-NM2 (SEQ ID NO: 11): 
cttggcagac gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat gctaacccag 
gaacaggatc agcaactggt tgaacgggta cagcgcggag acaagcgggc tttcgatctg ctggtactga 
aataccagca caagatactg ggattgatcg tgcggttcgt gcacgacgcc caggaagccc aggacgtagc 
gcaggaagcc ttcatcaagg cataccgtgc gctcggcaat ttccgcggcg atagtgcttt ttatacctgg 
ctgtatcgga tcgccatcaa caccgcgaag aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg 
atgtgaccgc agaggatgcg gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg 
ggcgatgttg cgggatgaga tcgaggccac cgtgcaccag accatccagc agttgcccga ggatttgcgc 
acggccctga ccctctgcgc gagttcgaag gtttgagtta cgaagatatc gccaccgtga tgcagtgtcc 
ggtggggacg gtacggtcgc ggatcttccg cgctcgtgaa gcaatcgaca aagctctgca gcctttgttg 
cgagaagcct gacacagcgg caaatgccaa gagaggta 
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VE3-NM3 (SEQ ID NO: 12): 
tatcttggca agacgattcg ctgggacgct cgaagctcct ccaggttcga agaggagctt tcatgctaac 
ccaggaacag gatcagcaac tggttgaacg ggtacagcgc ggagacaagc gggctttcga tctgctggta 
ctgaaatacc agcacaagat actgggattg atcgtgcggt tcgtgcacga cgcccaggaa gcccaggacg 
tagcgcagga agccttcatc aaggcatacc gtgcgctcgg caatttccgc ggcgatagtg ctttttatac 
ctgactgtat cggatcgcca tcaacaccgc gaagaaccac ctggtcgctc gcgggcgtcg gccaccggac 
agcgatgtga ccgcagagga tgcggagttc ttcgagggcg accacgccct gaaggacatc gagtcgccgg 
aacgggcgat gttgcgggat gagatcgagg ccaccgtgca ccagaccatc cagcagttgc ccgaggattt 
gcgcacggcc ctgaccctgc gcgagttcga aggtttgagt tacgaagata tcgccaccgt gatgcagtgt 
ccggtgggga cggtacggtc gcggatcttc cgcgctcgtg aagcaatcga caaagctctg cagcctttgt 
tgcgagaagc ctgacacagc ggcaaatgcc aagagagta 
VE3-NM4 (SEQ ID NO: 13): 
gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat gctaacccag gaacaggatc 
agcaactggt tgaacgggta cagcgcggag acaagcgggc tttcgatctg ctggtactga aataccagca 
caagatactg ggattgatcg tgcggttcgt gcacgacgcc caggaagccc aggacgtagc gcaggaagcc 
ttcatcaagg cataccgtgc gctcggcaat ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga tcgccatcaa 
caccgcgaag aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc agaggatgcg 
gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg ggcgatgttg cgggatgaga 
tcgaggccac cgtgcaccag accatccagc agttgcccga ggatttgcgc acggccctga ccctgcgcga 
gttcgaaggt ttgagttacg aagatatcgc caccgtgatg cagtgtccgg tggggacggt gtccggtggg 
gacggtacgg tcgcggatct tccgcgctcg tgaagcaatc gacaaagctc tgcagccttt gttgcgagaa 
gcctgacaca gcggcaaatg ccaagagagg to 
These mutations resulted in the disappearance ofAlgUand mutants (FIG. 8B vs. 6A-8A). This supports the notion that 
MucB in these mutants (FIG. 813). The suppressor mutants the mucAB and oprL genes negatively regulate the activity of 
were complemented to Alg' by a1gU in trans. The comple- A1gU (Firoved, A. M. & Deretic, V., JBacteriol 185:1071- 
mented mutants, which restored the mucoid phenotype, 40 1081 (2003); Mathee, K., et al., JBacteriol 179:3711-3720 
caused the re-appearance of A1gU (FIG. 813). We also mea- (1997)). 
sured the A1gU-dependent PI promoter activity by fusing the 
PajgUpl to the lacZ gene on the chromosome (DeVries, Example 7 
C. A. & Ohman, D. E., J Bacteriol 176:6677-6687 (1994); 
Schurr, M. 7., et al., J Bacteriol 176:3375-3382 (1995)). 45 Upregulation of A1gU (A1gT) Causes Mucoid Assay of the (3-galactosidase activity indicated that the Conversion PajgUPl  activity was 2348±156 units in NHl (algU') and 
16.0±5.5 units in NH3 (algU -) while that of the promoterless 
control in NH2 was 146±34 units (P=1.2x10 -5) (data not The mucoid phenotype in clinical isolates of P. aeruginosa 
shown). 	 50 is unstable, and non-mucoid revertants arise spontaneously in 
PA0579 is a relatively unstable mucoid mutant of PA01 the laboratory. Suppressor mutations in algT were the main 
origin with an undefined muc-23 mutation. A spontaneous cause ofmucoid suppression inP.. aeruginosa (DeVries, C.A. 
non-mucoid revertant, PA0579NM, was isolated which had & Ohman, D. E., JBacteriol 176:6677-6687 (1994); Schurr, 
an unknown suppressor mutation. The algUmucA alleles in M. 7., et al., JBacteriol 176:3375-3382 (1994)). FRD2 is a CF 
PA0579 and PA0579NM were sequenced but no mutations 55 isolate which has a suppressor mutation in algT18 (DeVries, 
were detected. To discern the pathway that regulated the C. A. & Ohman, D. E., JBacteriol 176:6677-6687 (1994)). 
mucoid phenotype 	 in 	 this 	 strain, 	 PA0579NM 	 was Three rare mucoid mutants were identified in FRD2 (Table 1). 
mutagenized to screen for mucoid mutants. Three sites, the They all had an insertion in front of a1gU, in the same manner 
a1gU promoter, the algUmucA intergenic region and mucA, as the a1gU promoter mutants in PA01 (VEI), PA14, and 
were targeted that reversed the phenotype to Alg' (Table 1). 60 PA0579NM, which resulted in increased transcription of the 
The highest frequency of mutations (60% within the strain) a1gT18mucA22mucBC operon as confirmed by Western 
occurred in the a1gU promoters causing increased levels of blots (FIG. 813). 
A1gU and MucB in the same fashion as in VEl in FIG. 5A The rare FRD2 mucoid mutants coupled with the upregu- 
(data not shown). lation ofA1gU support the notion thatAlgU is the only sigma 
The results show that inactivation of mucA and mucB did 65 factor controlling the expression of algD in P. aeruginosa 
not cause a marked induction in the amounts of A1gU and (FIG. 8). The results indicate that a suppressor nommucoid 
MucB to the same extent as the kinB, mucE and cupB5 mutant (FRD2) can revert back to a mucoid phenotype 
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(FRD2-VE1) in P. aeruginosa. This observation may help to 
explain why the a1gU suppressors are prevalent in clinical 
isolates. 
Analysis of the suppressor mutations in a1gU indicate that 
A1gU is required for alginate overproduction but is not an 
essential protein in P. aeruginosa. 
Example 8 
The Carboxyl Terminus of MucE Affects Mucoid 
Induction 
The carboxyl-terminal signal of MucE (WVF) has a simi-
lar three consensus as sequence as OmpC (YQF) (Walsh et 
al., 2003). Searching for this motif in the known outer mem-
brane protein database from PAOI did not identify any obvi-
ous E. coli OmpC homologs, indicating that mucE encodes a 
protein specific for induction of alginate. Other protein sig-
nals with such a function also exist. The C-terminal CupB5 
carries the three amino acid motif NIW. NIW and WVF are 
not interchangeable in MucE (unpublished observation), 
indicating that MucE and CupB5 work on different effector 
proteins in the periplasm. Table II shows the effect of altering 
the carboxyl terminus of MucE on mucoid induction in P. 
aeruginosa. 
TABLE II 
Alteration of C-terminal signal moiety of MucE and mucoidy 
induction in Pseudomonas aeruginosa PAOI. 
Carboxyl terminal Mucoidy 
sequences 	 induction 
Outer membrane proteins with 
the same C-terminal peptide 
WVF M MucE 
(Wild-type) 
YVF M OprP, OprQ 
LVF M MucE orthologue (P. fluoresces) 
WIF M MucE orthologue (P. syringae) 
WVW M 
WQF NM* 
YQF NM* OptS, HasR, OmpC and OmpF ofE. coli. 
WLF NM 
DRF NM AlgE 
YYF NM Strongest signal in E. coli 
YKF NM OprH (PAI178) 
FQF NM AlgI 
WWW NM 
WVA NM 
WVY NM 
ELR(AWVF) NM 
RWV (AF) NM 
M: mucoid.; NM: Non-mucoid; 
*Slightly mucoid after 1 day of incubation 
The results in Table II show that the last three carboxyl-
terminal amino acids of MucE, WVF, are critical for the 
ability of MucE to induce mucoid induction. 
Similarly, the WFV signal induced mucoidy in P. fluore-
scens. The WVF and YVF carboxyl terminal sequences sig-
nificantly induced mucoidy, while theYQF carboxyl terminal 
sequence did not (data not shown). The envelope signal is 
well conserved among Pseudomonads. Therefore, P. fluore-
scens is an alternative producer when alginate will be used for 
human consumption. 
Example 9 
MucE Interacts with A1gW Resulting in Alginate 
Overproduction 
36 
the chromosome of PAOI-VE2 causes this strain to become 
nonmucoid (Boucher, J. C., et al., J. Bacteriol. 178:511-523 
(1996)). Revertion back to the mucoid state occurs when a 
functional copy of algW is brought into the cells. Similarly, 
5 the disruption of algW in PAOI (PAOlAalgW) prevents 
mucoid induction even whenplasmid-borne mucE (pUCP20-
Gm'-mucE) was in a state of overexpression. MucE is found 
to interact with A1gW causing alginate overproduction by 
increasing the expression and/or activity of A1gU. 
10 Normally, A1gW is inactive because the functional domain 
(the trypsin domain) is covered with a PDZ domain of its own. 
Interaction between MucE and A1gW results in the release of 
the PDZ domain of A1gW. This interaction occurs via the 
15 carboxyl terminus of MucE, specifically the terminal amino 
acids WVF, resulting in the activation of A1gW. Activated 
A1gW degrades the carboxyl terminus of anti-sigma factor 
MucA. This action causes the release of A1gU into the cyto-
plasm, thereby activating alginate biosynthesis (see FIG. 9). 
20 A1gU is the sigma factor that drives alginate biosynthesis. 
Therefore, MucE is an inducing signal for alginate overpro-
duction and the periplasmic target of MucE is A1gW (see 
Table III). 
25 	 TABLE III 
MucE-mediated induction of mucoidy in the 
mucA' wild type P. aeruginosa is via AlgW. 
Bacterial strains Genotype Phenotype 
30 	 PAOI Wild type NM 
VE2 PAOI over-expressing mucE M 
VE2 algW KO VE2 algW knockout NM 
VE2 algW KO + VE2 algW KO + M 
pUCP20algW pUCP20 algW 
35 
The nucleotide sequence of algW (SEQ ID NO: 14) is as 
follows: 
40 ATGCCCAAGGCCCTGCGTTTCCTCGGCTGGCCCGTGCTGGTCGGCG 
TGCTGCTGGCCCTGCTGATCATCCAGCACAACCCCGAGCTGGTCGGCCTG 
CCACGCCAGGAGGTGCACGTCGAGCAGGCGCCTCTGCTCAGCCGCCTGCA 
GGAAGGCCCGGTGTCCTATGCCAACGCGGTGAGTCGAGCGGCTCCGGCAG 
45 
TGGCCAACCTGTACACCACCAAGATGGTCAGCAAGCCCTCCCACCCCCTG 
TTCGACGACCCGATGTTCCGCCGCTTCTTCGGCGACAACCTGCCGCAACA 
GAAGCGCATGGAGTCGAGCCTCGGCTCGGCGGTGATCATGAGCGCGGAAG 
50 
GCTACCTGCTGACCAACAACCACGTGACCGCTGGCGCCGACCAGATCATC 
GTGGCCTTGCGCGACGGCCGCGAAACCATCGCCCAGTTGGTCGGCAGCGA 
CCCGGAAACCGACCTGGCCGTGCTGAAGATCGACCTTAAGAACCTGCCGG 
55 
CGATGACCCTCGGCCGCTCCGACGGCATTCGCACCGGCGACGTCTGCCTC 
GCCATCGGCAACCCGTTCGGCGTCGGCCAGACCGTGACCATGGGCATCAT 
CAGCGCCACCGGACGCAACCAGCTCGGCCTGAACACCTACGAAGACTTCA 
60 TCCAGACCGACGCGGCGATCAACCCCGGCAACTCCGGCGGCGCGCTGGTG 
GACGCTGCCGGCAACCTGATCGGCATCAACACGGCGATCTTCTCCAAGTC 
CGGCGGCTCCCAGGGTATCGGCTTCGCCATCCCGACCAAGCTGGCCCTGG 
65 AGGTCATGCAGTCGATCATCGAGCACGGCCAGGTGATCCGCGGCTGGCTC 
A1gW (GenBank accession number (U29172) is a periplas-
mic serine protease in P. aeruginosa. Inactivation of algW on 
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GGCGTCGAGGTCAAGGCGCTGACCCCGGAACTGGCGGAGTCGCTGGGCCT 
CGGCGAAACCGCCGGGATCGTCGTCGCCGGCGTCTATCGCGACGGTCCGG 
CGGCACGCGGCGGCCTGCTGCCGGGCGATGTGATCCTGACCATCGACAAG 5 
38 
Example 11 
MucP is Essential for MucE-Induced Conversion to 
Mucoidy 
CAGGAAGCCAGCGACGGCCGCCGCTCGATGAACCAGGTGGCGCGCACCC 
GTCCGGGACAGAAGATCAGCATCGTGGTGCTGCGCAACGGACAGAAGGT 
CAACCTGACCGCCGAGGTCGGCCTGCGTCCGCCGCCGGCACCGGCTCCAC 
AGCAGAAACAGGACGGCGGCGAGTGA 
The amino acid sequence of A1gW (SEQ ID NO: 15) is as 
follows: 
MPKALRFLGWPVLVGVLLALLIIQHNPELVGLPRQEVHVEQAPLLSRL 
QEGPVSYANAVSRAAPAVANLYTTKMVSKPSHPLFDDPMFRRFFGDNLP 
QQKRMESSLGSAVIMSAEGYLLTNNHVTAGADQIIVALRDGRETIAQLVG 
SDPETDLAVLKIDLKNLPAMTLGRSDGIRTGDVCLAIGNPFGVGQTVTMG 
AIISTGRNQLGLNTYEDFIQTDAAINPGNSGGALVDAAGNLIGINTAIFS 
In E. coli, the degradation of RseA requires another pro-
tease called RseP (also known as YaeL) to cleave the anti-
sigma factor RseA after it is cleaved by DegS (Alba, B. M., et 
al., Genes Dev 16:2156-2168 (2002); Kanehara, K., et al., 
10 Embo J 22:6389-6398 (2003)). The P. aeruginosa genome 
also contains a homolog of RseP (PA3649, designated as 
MucP) (FIG. 15). The role of MucP in the degradation of 
MucA and activation of A1gU activity was examined. Inacti-
vation of mucP in PAOI VE2 caused a loss of mucoidy. Fur- 
15 thermore, the plasmid pUCP20 (pUCP20-mucP) restored the 
mucoid phenotype in PAOI VE2AmucP. Similarly, disruption 
of mucP in PAO1 prevented mucoid conversion when a high 
level of MucE was present from plasmid pUC20-Gmr-mucE. 
In addition, a higher level of MucA and a lower level of A1gU 
20 in PAOIVE2AmucP as compared to PAOIVE2 (data not 
shown) was seen. These results indicate that MucP is required 
for MucE activation ofA1gU activity. 
Example 12 
KQSGGSGIGFAIPTKLALEVMQSIIEHGQVIRGWLGVEVKALTPELAESL 25 
GLGETAGIVVAGVYRDGPAARGGLLPGDVILTIDKQEASDGRRSMNQV 
GARTRPQKISIVVLRNGQKVNLTAEVGLRPPPAPAPQQKQDGGE 
MucE-Induced Mucoidy does not Require the Prc 
Protease 
The homolog ofA1gW is DegS inE. coli (see also FIG. 12). 
The interaction between DegS and OmpC, an outer mem-
brane porin protein, has been shown to activate the signal 
transduction pathway for the activation of RpoE, the A1gU 
homolog in E. coli. It has been shown that interaction between 
OmpC and DegS in the periplasm activates the signal trans-
duction pathway that controls the expression and/or activity 
of RpoE, a homolog of A1gU (Walsh, N. P., et al., Cell 113: 
61-71 (2003)). 
The results suggest that MucE functions upstream of the 
anti-sigma factor MucA. 
Example 10 
The MucE Gene Encodes a Small Periplasmic or 
Outer Membrane Protein 
The mucE gene is predicted to encode a polypeptide of 89 
amino acids with a probable transmembrane helix and a 
cleavable N-terminal signal sequence. (Stover, C. K., et al., 
Nature 406:959-964 (2000)). Homologues of MucE are 
found in other species of p seudomonads capable of producing 
alginate (FIG. 11). We confirmed that mucE encodes a protein 
by detecting an approximately 10 kD protein in Western blots 
of cell extracts of E. coli and P. aeruginosa expressing His-
tagged MucE (FIG. 13). PseudoCAP and Signal IP servers 
predicted that MucE is likely to be located in the periplasm. 
To test the localization of MucE, we constructed a series of 
deletions of mucE-phoA translational fusions. We observed 
phosphatase activity when phoA was fused to sequence cor-
responding to the full-length MucE or the N-terminus after 
P36 but not after A25. The MucE C-terminus-PhoA fusion 
did not show apparent phosphatase activity (FIG. 14). These 
results indicate that MucE is a small protein of about 9.5 kDa 
located in the periplasm or outer membrane, with an N-ter-
minal signal sequence that is required for translocation across 
the cytoplasmic membrane. 
The gene prc (PA3257) was recently identified as a regu- 
30 lator of alginate synthesis in P. aeruginosa and is predicted to 
encode a PDZ domain-containing periplasmic protease simi- 
lar to a E. coli protease called Prc or Tsp (Reiling S. A., et al., 
Microbiology 151:2251-2261 (2005)). Prc appears to act to 
promote mucoidy in mucA mutants by degrading truncated 
35 forms of MucA found in mucoid mucA mutants (Reiling S. 
A., et al., Microbiology 151:2251-2261 (2005)). To test 
whether Prc plays a role in the activation of alginate produc- 
tion mediated by MucE, MucE was overexpressed in a strain 
lacking Prc and examined for mucoidy. Cells of the prc null 
40 mutant PAOI-184 (prc::tetR) carrying either MucE overex- 
pression plasmid pUCP20-Gmr-mucE or pUCP20-PGm- 
mucE were as mucoid as PAOI cells carrying pUCP20-Gmr- 
mucE or pUCP20-PGm-mucE. These results suggest that Prc 
is not required for mucoidy induced by MucE and is consis- 
45 tent with Prc only acting against truncated forms of MucA. 
Example 13 
MucD Eliminates Signal Proteins that Activate A1gW 
50 	 and Other Proteasesto Cleave MucA 
The mucD gene (PA0766) is a member of the a1gU 
mucABCD operon and is predicted to encode a serine pro-
tease similar to HtrA in E. coli (Boucher, C. 7., et al., J. 
55 Bacteriol. 178:511-523 (1996)). MucD appears to be a nega-
tive regulator of mucoidy andAlgU activity (Boucher, C. 7., et 
al., J. Bacteriol. 178:511-523 (1996)). The mariner transpo-
son library screen confirmed this result because several 
mucoid mutants were isolated that had transposons inserted 
60 within the coding region of mucD. HtrA in E. coli has been 
hypothesized to regulate the u E stress response system by 
removing misfolded proteins in the periplasm that can acti-
vate the DegS protease via the degradation of the anti-sigma 
factor RseA (Alba, B. M., et al., Genes Dev. 16:2156-2168 
65 (2002); Kanehara, K., et al., Embo J. 22:6389-6398 (2003)). 
Therefore, it was determined whether MucD of P. aeruginosa 
acted in a similar manner as HtrA of E. coli. To test this, 
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overexpression of MucD in a strain overexpressing MucE 
was examined Overexpression of mucD from the plasmid 
pUCP20-mucD partially suppressed the mucoid phenotype 
of the mucE-overexpressing strain PAOI VE2. This result is 
consistent with the notion that MucD can aid in the elimina-
tion of mis-folded OMPs including MucE. In addition, dis-
ruption of mucD in the mucoid mucD mutant PAOIVE19 
caused the loss of the mucoid phenotype. The mucoid phe- 
40 
notype of PAOI VEI Mum P was restored when mucD was in 
trans. Loss of the mucoid phenotype from the mucD mutant 
PAOIVE19 after the disruption of algW was not observed. 
The results suggest that MucD can act to remove misfolded 
s proteins that activate proteases for degradation of MucA and 
that at least under certain conditions other proteases indepen-
dent of A1gW can also initiate the cleavage of MucA. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 	 37 
<210> SEQ ID NO 1 
<211> LENGTH: 	 270 
<212> TYPE: DNA 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 	 1 
atgggtttcc ggccagttag ccaacgtttg cgtgacatca acctgcaggc cctcggcaag 60 
ttttcctgcc ttgccctggt cctcggcctg gaatcggtaa gccatccggc cggcccggtc 120 
caggccccct cgttcagcca gggcaccgcc agcccgtcct tcgctactcc gctcggcctc 180 
gacggcccgg cccgcgccag ggccgagatg tggaacgtcg gcctgtccgg cgccgtcagc 240 
gtgcgtgacg agttgcgctg ggtgttttga 270 
<210> SEQ ID NO 2 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 2 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 3 
<211> LENGTH: 	 288 
<212> TYPE: DNA 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 	 3 
atggggaacc tgctcaggaa aggccaggtc gcgcttgtca gaatattcag cggcgatgat 60 
ccggtgcgtc ttctcagttt gatgctggcg gcttatctgg gaatcagtgc ctgtaccgtg 120 
ccagcgtcca cagcgggctg ctgtcagccc tccggcatag ggcaataccc ggcgtctgcc 180 
ctgcccgctg gcagtgactc caacctgacc ctggacgccg agcccgtgat cggtcggaca 240 
gcgctaccca cgaacctgca gccaccggcc ccgcgctggg tgttctag 288 
<210> SEQ ID NO 4 
<211> LENGTH: 	 95 
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-continued 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 4 
Met Gly Asn Leu Leu Arg Lys Gly Gin Val Ala Leu Val Arg Ile Phe 
1 	 5 	 10 	 15 
Ser Gly Asp Asp Pro Val Arg Leu Leu Ser Leu Met Leu Ala Ala Tyr 
20 	 25 	 30 
Leu Gly Ile Ser Ala Cys Thr Val Pro Ala Ser Thr Ala Gly Cys Cys 
35 	 40 	 45 
Gin Pro Ser Gly Ile Gly Gin Tyr Pro Ala Ser Ala Leu Pro Ala Gly 
50 	 55 	 60 
Ser Asp Ser Asn Leu Thr Leu Asp Ala Glu Pro Val Ile Gly Arg Thr 
65 	 70 	 75 	 80 
Ala Leu Pro Thr Asn Leu Gin Pro Pro Ala Pro Arg Trp Val Phe 
85 	 90 	 95 
<210> SEQ ID NO 5 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide 
sequence designed to form hybridized complexes 
<400> SEQUENCE: 5 
tcaaaacacc cagcgcaact cgtcacg 	 27 
<210> SEQ ID NO 6 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide 
sequence designed to form hybridized complexes 
<400> SEQUENCE: 6 
agtagcgaag gacgggctgg cggt 	 24 
<210> SEQ ID NO 7 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic complementary oligonucleotide 
sequence designed to form hybridized complexes 
<400> SEQUENCE: 7 
ttggctaact ggccggaaac ccat 	 24 
<210> SEQ ID NO 8 
<211> LENGTH: 1473 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of mariner transposon's 
junction region 
<400> SEQUENCE: 8 
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt cccattcgcc actcaaccaa 	 60 
gtcattctga gaatagtgta tgcggcgacc gagttgctct tgcccggcgt caatacggga 120 
taataccgcg ccacataaca ggttggctga taagtccccg gtctaacaaa gaaaaacaca 180 
tttttttgtg aaaattcgtt tttattattc aacatagttc ccttcaagag cgatacccct 240 
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44 
-continued 
cgaattgacg cgtcaattct cgaattgaca taagcctgtt cggttcgtaa actgtaatgc 	 300 
aagtagcgta tgcgctcacg caactggtcc agaaccttga ccgaacgcag cggtggtaac 	 360 
ggcgcagtgg cggttttcat ggcttgttat gactgttttt ttgtacagtc tatgcctcgg 	 420 
gcatccaagc agcaagcgcg ttacgccgtg ggtcgatgtt tgatgttatg gagcagcaac 	 480 
gatgttacgc agcagcaacg atgttacgca gcagggcagt cgccctaaaa caaagttagg 	 540 
tggctcaagt atgggcatca ttcgcacatg taggctcggc cctgaccaag tcaaatccat 	 600 
gcgggctgct cttgatcttt tcggtcgtga gttcggagac gtagccacct actcccaaca 	 660 
tcagccggac tccgattacc tcgggaactt gctccgtagt aagacattca tcgcgcttgc 	 720 
tgccttcgac caagaagcgg ttgttggcgc tctcgcggct tacgttctgc ccaggtttga 	 780 
gcagccgcgt agtgagatct atatctatga tctcgcagtc tccggcgagc accggaggca 	 840 
gggcattgcc accgcgctca tcaatctcct caagcatgag gccaacgcgc ttggtgctta 	 900 
tgtgatctac gtgcaagcag attacggtga cgatcccgca gtggctctct atacaaagtt 	 960 
gggcatacgg gaagaagtga tgcactttga tatcgaccca agtaccgcca cctaacaatt 	 1020 
cgttcaagcc gagatcggct tcccggccga cgcgtcctcg gtaccgggcc ccccctcgag 	 1080 
gtcgacggta tcgataagct tgatatcgaa ttcctgcagc ccgggaatca tttgaaggtt 	 1140 
ggtactatat aaaaataata tgcatttaat actagcgacg ccatctatgt gtcagaccgg 	 1200 
ggacttatca gccaacctgt tagcagaact ttaaaagtgc tcatcattgg aaaaaggctg 	 1260 
cgcaactgtt gggaagggcg atcggtgcgg gcctcttcgc tattacgcca gctggcgaaa 	 1320 
gggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 	 1380 
tgtaaaacga cggccagtga gcgcgcgtaa tacactcact atagggcgaa ttggaggatc 	 1440 
cggtctaaca aagaaaacac attttttgtg aaa 	 1473 
<210> SEQ ID NO 9 
<211> LENGTH: 5622 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of pUCP20-Gm-MucE plasmid 
<400> SEQUENCE: 9 
gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 	 60 
cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 	 120 
tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 	 180 
aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 	 240 
ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 	 300 
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 	 360 
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 	 420 
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 	 480 
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 	 540 
gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 	 600 
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 	 660 
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 	 720 
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 	 780 
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 	 840 
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-continued 
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 	 900 
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 	 960 
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 	 1020 
agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 	 1080 
catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 	 1140 
tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 	 1200 
cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct 	 1260 
gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 	 1320 
taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 	 1380 
ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 	 1440 
tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 	 1500 
ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 	 1560 
cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 	 1620 
agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 	 1680 
gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 	 1740 
atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 	 1800 
gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 	 1860 
gctggccttt tgctcacata agctagctta tcggccagcc tcgcagagca ggattcccgt 	 1920 
tgagcaccgc caggtgcgaa taagggacag tgaagaagga acacccgctc gcgggtgggc 	 1980 
ctacttcacc tatcctgccc ggctgacgcc gttggataca ccaaggaaag tctacacgaa 	 2040 
ccctttggca aaatcctgta tatcgtgcga aaaaggatgg atataccgaa aaaatcgcta 	 2100 
taatgacccc gaagcagggt tatgcagcgg aaagtatacc ttaaggaatc cccatgttct 	 2160 
ttcctgcgtt atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata 	 2220 
ccgctcgccg cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 	 2280 
gcccaatacg caaaccgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg 	 2340 
acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agttagctca 2400 
ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatgttg tgtggaattg 	 2460 
tgagcggata acaatttcac acaggaaaca gctatgacca tgattacgaa ttcgagctcg 	 2520 
gtaccctagc ctgattccaa atagccatta agcgggacga agagcccgtg agccagcgcc 	 2580 
agcctgacct aacaggttgg ctgataagtc cccggtctaa caaagaaaaa cacatttttt 	 2640 
tgtgaaaatt cgtttttatt attcaacata gttcccttca agagcgatac ccctcgaatt 	 2700 
gacgcgtcaa ttctcgaatt gacataagcc tgttcggttc gtaaactgta atgcaagtag 	 2760 
cgtatgcgct cacgcaactg gtccagaacc ttgaccgaac gcagcggtgg taacggcgca 	 2820 
gtggcggttt tcatggcttg ttatgactgt ttttttgtac agtctatgcc tcgggcatcc 	 2880 
aagcagcaag cgcgttacgc cgtgggtcga tgtttgatgt tatggagcag caacgatgtt 	 2940 
acgcagcagc aacgatgtta cgcagcaggg cagtcgccct aaaacaaagt taggtggctc 	 3000 
aagtatgggc atcattcgca catgtaggct cggccctgac caagtcaaat ccatgcgggc 	 3060 
tgctcttgat cttttcggtc gtgagttcgg agacgtagcc acctactccc aacatcagcc 	 3120 
ggactccgat tacctcggga acttgctccg tagtaagaca ttcatcgcgc ttgctgcctt 	 3180 
cgaccaagaa gcggttgttg gcgctctcgc ggcttacgtt ctgcccaggt ttgagcagcc 	 3240 
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-continued 
gcgtagtgag atctatatct atgatctcgc agtctccggc gagcaccgga ggcagggcat 	 3300 
tgccaccgcg ctcatcaatc tcctcaagca tgaggccaac gcgcttggtg cttatgtgat 	 3360 
ctacgtgcaa gcagattacg gtgacgatcc cgcagtggct ctctatacaa agttgggcat 	 3420 
acgggaagaa gtgatgcact ttgatatcga cccaagtacc gccacctaac aattcgttca 	 3480 
agccgagatc ggcttcccgg ccgacgcgtc ctcggtaccg ggccccccct cgaggtcgac 	 3540 
ggtatcgata agcttgatat cgaattcctg cagcccggga atcatttgaa ggttggtact 	 3600 
atataaaaat aatatgcatt taatactagc gacgccatct atgtgtcaga ccggggactt 	 3660 
atcagccaac ctgttatcaa ggagtcgtag ccatgggttt ccggccagtt agccaacgtt 	 3720 
tgcgtgacat caacctgcag gccctcggca agttttcctg ccttgccctg gtcctcggcc 	 3780 
tggaatcggt aagccatccg gccggcccgg tccaggcccc ctcgttcagc cagggcaccg 	 3840 
ccagcccgtc cttcgctact ccgctcggcc tcgacggccc ggcccgcgcc agggccgaga 	 3900 
tgtggaacgt cggcctgtcc ggcgccgtca gcgtgcgtga cgagttgcgc tgggtgtttt 	 3960 
gaacgcgaag cttaggggat cctctagagt cgacctgcag gcatgcaagc ttggcactgg 4020 
ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt tacccaactt aatcgccttg 	 4080 
cagcacatcc ccctttcgcc agctggcgta atagcgaaga ggcccgcacc gatcgccctt 	 4140 
cccaacagtt gcgcagcctg aaaggcaggc cgggccgtgg tggccacggc ctctaggcca 4200 
gatccagcgg catctgggtt agtcgagcgc gggccgcttc ccatgtctca ccagggcgag 	 4260 
cctgtttcgc gatctcagca tctgaaatct tcccggcctt gcgcttcgct ggggccttac 	 4320 
ccaccgcctt ggcgggcttc ttcggtccaa aactgaacaa cagatgtgtg accttgcgcc 	 4380 
cggtctttcg ctgcgcccac tccacctgta gcgggctgtg ctcgttgatc tgcgtcacgg 	 4440 
ctggatcaag cactcgcaac ttgaagtcct tgatcgaggg ataccggcct tccagttgaa 	 4500 
accactttcg cagctggtca atttctattt cgcgctggcc gatgctgtcc cattgcatga 	 4560 
gcagctcgta aagcctgatc gcgtgggtgc tgtccatctt ggccacgtca gccaaggcgt 	 4620 
atttggtgaa ctgtttggtg agttccgtca ggtacggcag catgtctttg gtgaacctga 	 4680 
gttctacacg gccctcaccc tcccggtaga tgattgtttg cacccagccg gtaatcatca 	 4740 
cactcggtct tttccccttg ccattgggct cttgggttaa ccggacttcc cgccgtttca 	 4800 
ggcgcagggc cgcttctttg agctggttgt aggaagattc gatagggaca cccgccatcg 4860 
tcgctatgtc ctccgccgtc actgaataca tcacttcatc ggtgacaggc tcgctcctct 	 4920 
tcacctggct aatacaggcc agaacgatcc gctgttcctg aacactgagg cgatacgcgg 	 4980 
cctcgaccag ggcattgctt ttgtaaacca ttgggggtga ggccacgttc gacattcctt 	 5040 
gtgtataagg ggacactgta tctgcgtccc acaatacaac aaatccgtcc ctttacaaca 	 5100 
acaaatccgt cccttcttaa caacaaatcc gtcccttaat ggcaacaaat ccgtcccttt 	 5160 
ttaaactcta caggccacgg attacgtggc ctgtagacgt cctaaaaggt ttaaaaggga 	 5220 
aaaggaagaa aagggtggaa acgcaaaaaa cgcaccacta cgtggccccg ttggggccgc 	 5280 
atttgtgccc ctgaaggggc gggggaggcg tctgggcaat ccccgtttta ccagtcccct 	 5340 
atcgccgcct gagagggcgc aggaagcgag taatcagggt atcgaggcgg attcaccctt 	 5400 
ggcgtccaac cagcggcacc agcggcgcct gagaggtatg gtgcactctc agtacaatct 	 5460 
gctctgatgc cgcatagtta agccagcccc gacacccgcc aacacccgct gacgcgccct 	 5520 
gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc tccgggagct 	 5580 
gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc ga 	 5622 
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<210> SEQ ID NO 10 
<211> LENGTH: 674 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM1 
<400> SEQUENCE: 10 
cgattcgctg ggacgctcga agctcctcca ggttcgaaga ggagctttca tgctaaccca 	 60 
ggaacaggat cagcaactgg ttgaacgggt acagcgcgga gacaagcggg ctttcgatct 	 120 
gctggtactg aaataccagc acaagatact gggattgatc gtgcggttcg tgcacgacgc 	 180 
ccaggaagcc caggacgtag cgcaggaagc cttcatcaag gcataccgtg cgctcggcaa 	 240 
tttccgcggc gatagtgctt tttatacctg gctgtatcgg atcgccatca acaccgcgaa 	 300 
gaaccacctg gtcgctcgcg ggcgtcggcc accggacagc gatgtgaccg cagaggatgc 	 360 
ggagttcttc gagggcgacc acgccctgaa ggacatcgag tcgccggaac gggcgatgtt 	 420 
gcgggatgag atcgaggcca ccgtgcacca gaccatccag cagttgcccg aggatttgcg 	 480 
cacggccctg accctgcgcg agttcgaagg tttgagttac gaagatatcg ccaccgtgat 	 540 
gcagtgtccg gtggggacgg tgtccggtgg ggacggtacg gtcgcggatc ttccgcgctc 	 600 
gtgaagcaat cgacaaagct ctgcagcctt tgttgcgaga agcctgacac agcggcaaat 	 660 
gccaagagag gtta 	 674 
<210> SEQ ID NO 11 
<211> LENGTH: 668 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM2 
<400> SEQUENCE: 11 
cttggcagac gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat 	 60 
gctaacccag gaacaggatc agcaactggt tgaacgggta cagcgcggag acaagcgggc 	 120 
tttcgatctg ctggtactga aataccagca caagatactg ggattgatcg tgcggttcgt 	 180 
gcacgacgcc caggaagccc aggacgtagc gcaggaagcc ttcatcaagg cataccgtgc 	 240 
gctcggcaat ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga tcgccatcaa 	 300 
caccgcgaag aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc 	 360 
agaggatgcg gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg 	 420 
ggcgatgttg cgggatgaga tcgaggccac cgtgcaccag accatccagc agttgcccga 	 480 
ggatttgcgc acggccctga ccctctgcgc gagttcgaag gtttgagtta cgaagatatc 	 540 
gccaccgtga tgcagtgtcc ggtggggacg gtacggtcgc ggatcttccg cgctcgtgaa 	 600 
gcaatcgaca aagctctgca gcctttgttg cgagaagcct gacacagcgg caaatgccaa 	 660 
gagaggta 	 668 
<210> SEQ ID NO 12 
<211> LENGTH: 669 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM3 
<400> SEQUENCE: 12 
tatcttggca agacgattcg ctgggacgct cgaagctcct ccaggttcga agaggagctt 	 60 
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tcatgctaac ccaggaacag gatcagcaac tggttgaacg ggtacagcgc ggagacaagc 120 
gggctttcga tctgctggta ctgaaatacc agcacaagat actgggattg atcgtgcggt 180 
tcgtgcacga cgcccaggaa gcccaggacg tagcgcagga agccttcatc aaggcatacc 240 
gtgcgctcgg caatttccgc ggcgatagtg ctttttatac ctgactgtat cggatcgcca 300 
tcaacaccgc gaagaaccac ctggtcgctc gcgggcgtcg gccaccggac agcgatgtga 360 
ccgcagagga tgcggagttc ttcgagggcg accacgccct gaaggacatc gagtcgccgg 420 
aacgggcgat gttgcgggat gagatcgagg ccaccgtgca ccagaccatc cagcagttgc 480 
ccgaggattt gcgcacggcc ctgaccctgc gcgagttcga aggtttgagt tacgaagata 540 
tcgccaccgt gatgcagtgt ccggtgggga cggtacggtc gcggatcttc cgcgctcgtg 600 
aagcaatcga caaagctctg cagcctttgt tgcgagaagc ctgacacagc ggcaaatgcc 660 
aagagagta 669 
<210> SEQ ID NO 13 
<211> LENGTH: 672 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic sequence of algU mutant, VE3-NM4 
<400> SEQUENCE: 13 
gattcgctgg gacgctcgaa gctcctccag gttcgaagag gagctttcat gctaacccag 	 60 
gaacaggatc agcaactggt tgaacgggta cagcgcggag acaagcgggc tttcgatctg 	 120 
ctggtactga aataccagca caagatactg ggattgatcg tgcggttcgt gcacgacgcc 	 180 
caggaagccc aggacgtagc gcaggaagcc ttcatcaagg cataccgtgc gctcggcaat 	 240 
ttccgcggcg atagtgcttt ttatacctgg ctgtatcgga tcgccatcaa caccgcgaag 	 300 
aaccacctgg tcgctcgcgg gcgtcggcca ccggacagcg atgtgaccgc agaggatgcg 	 360 
gagttcttcg agggcgacca cgccctgaag gacatcgagt cgccggaacg ggcgatgttg 	 420 
cgggatgaga tcgaggccac cgtgcaccag accatccagc agttgcccga ggatttgcgc 	 480 
acggccctga ccctgcgcga gttcgaaggt ttgagttacg aagatatcgc caccgtgatg 	 540 
cagtgtccgg tggggacggt gtccggtggg gacggtacgg tcgcggatct tccgcgctcg 	 600 
tgaagcaatc gacaaagctc tgcagccttt gttgcgagaa gcctgacaca gcggcaaatg 	 660 
ccaagagagg to 	 672 
<210> SEQ ID NO 14 
<211> LENGTH: 	 1170 
<212> TYPE: DNA 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 	 14 
atgcccaagg ccctgcgttt cctcggctgg cccgtgctgg tcggcgtgct gctggccctg 60 
ctgatcatcc agcacaaccc cgagctggtc ggcctgccac gccaggaggt gcacgtcgag 120 
caggcgcctc tgctcagccg cctgcaggaa ggcccggtgt cctatgccaa cgcggtgagt 180 
cgagcggctc cggcagtggc caacctgtac accaccaaga tggtcagcaa gccctcccac 240 
cccctgttcg acgacccgat gttccgccgc ttcttcggcg acaacctgcc gcaacagaag 300 
cgcatggagt cgagcctcgg ctcggcggtg atcatgagcg cggaaggcta cctgctgacc 360 
aacaaccacg tgaccgctgg cgccgaccag atcatcgtgg ccttgcgcga cggccgcgaa 420 
accatcgccc agttggtcgg cagcgacccg gaaaccgacc tggccgtgct gaagatcgac 480 
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cttaagaacc tgccggcgat gaccctcggc cgctccgacg gcattcgcac cggcgacgtc 	 540 
tgcctcgcca tcggcaaccc gttcggcgtc ggccagaccg tgaccatggg catcatcagc 	 600 
gccaccggac gcaaccagct cggcctgaac acctacgaag acttcatcca gaccgacgcg 	 660 
gcgatcaacc ccggcaactc cggcggcgcg ctggtggacg ctgccggcaa cctgatcggc 	 720 
atcaacacgg cgatcttctc caagtccggc ggctcccagg gtatcggctt cgccatcccg 	 780 
accaagctgg ccctggaggt catgcagtcg atcatcgagc acggccaggt gatccgcggc 	 840 
tggctcggcg tcgaggtcaa ggcgctgacc ccggaactgg cggagtcgct gggcctcggc 	 900 
gaaaccgccg ggatcgtcgt cgccggcgtc tatcgcgacg gtccggcggc acgcggcggc 	 960 
ctgctgccgg gcgatgtgat cctgaccatc gacaagcagg aagccagcga cggccgccgc 	 1020 
tcgatgaacc aggtggcgcg cacccgtccg ggacagaaga tcagcatcgt ggtgctgcgc 	 1080 
aacggacaga aggtcaacct gaccgccgag gtcggcctgc gtccgccgcc ggcaccggct 	 1140 
ccacagcaga aacaggacgg cggcgagtga 	 1170 
<210> SEQ ID NO 15 
<211> LENGTH: 389 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 15 
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val 
1 	 5 	 10 	 15 
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu 
20 	 25 	 30 
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu 
35 	 40 	 45 
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro 
50 	 55 	 60 
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His 
65 	 70 	 75 	 80 
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu 
85 	 90 	 95 
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met 
100 	 105 	 110 
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala 
115 	 120 	 125 
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin 
130 	 135 	 140 
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp 
145 	 150 	 155 	 160 
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg 
165 	 170 	 175 
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin 
180 	 185 	 190 
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly 
195 	 200 	 205 
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Pro 
210 	 215 	 220 
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly 
225 	 230 	 235 	 240 
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly 
245 	 250 	 255 
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Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gln Ser Ile Ile 
260 	 265 	 270 
Glu His Gly Gln Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala 
275 	 280 	 285 
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly 
290 	 295 	 300 
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly 
305 	 310 	 315 	 320 
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gln Glu Ala Ser 
325 	 330 	 335 
Asp Gly Arg Arg Ser Met Asn Gln Val Ala Arg Thr Arg Pro Gly Gln 
340 	 345 	 350 
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gln Lys Val Asn Leu Thr 
355 	 360 	 365 
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gln Gln Lys 
370 	 375 	 380 
Gln Asp Gly Gly Glu 
385 
<210> SEQ ID NO 16 
<211> LENGTH: 	 547 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic algU promoter region 
<400> SEQUENCE: 	 16 
agtaggtcga gccctgcgac agttcgccct tgctgaggac ggcgatgcgc aggtgttccg 60 
gaagggtcaa ggccagactc aggccggcgg cgccgctgcc gatgaccagt acatcgtgtt 120 
gataatgttg gctcatgccc gcatttcccc gtggtggagc cctagtatat agaagggcct 180 
ggcggcacaa tagcgcaccc ccgctgccgg tccggcggat gagctgcggg cctgtcatcg 240 
gcaggcgtca tcagagcggg gcgatgtagt gctggaactt tcttagacgc atcggttcca 300 
aagcaggatg cctgaagacc tcgtccggtt ggcctaccca gcggcacaga ggccgggccc 360 
tgagcccgat gcaatccatt ttcgcggggc ccggacacga tgtccggggc cgcacgtcac 420 
gagcgaggaa aaaactcgtg acgcatgctt ggaggggaga acttttgcaa gaagcccgag 480 
tctatcttgg caagacgatt cgctgggacg ctcgaagctc ctccaggttc gaagaggagc 540 
tttcatg 547 
<210> SEQ ID NO 17 
<211> LENGTH: 306 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic mucE gene 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (18)..(18) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 17 
agcgccagcc tgacctanta tcaaggagtc gtagccatgg gtttccggcc agttagccaa 	 60 
cgtttgcgtg acatcaacct gcaggccctc ggcaagtttt cctgccttgc cctggtcctc 120 
ggcctggaat cggtaagcca tccggccggc ccggtccagg ccccctcgtt cagccagggc 180 
accgccagcc cgtccttcgc tactccgctc ggcctcgacg gcccggcccg cgccagggcc 240 
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gagatgtgga acgtcggcct gtccggcgcc gtcagcgtgc gtgacgagtt gcgctgggtg 	 300 
ttttga 	 306 
<210> SEQ ID NO 18 
<211> LENGTH: 450 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic E. coli orthologue RseP peptide 
<400> SEQUENCE: 18 
Met Leu Ser Phe Leu Trp Asp Leu Ala Ser Phe Ile Val Ala Leu Gly 
1 	 5 	 10 	 15 
Val Leu Ile Thr Val His Glu Phe Gly His Phe Trp Val Ala Arg Arg 
20 	 25 	 30 
Cys Gly Val Arg Val Glu Arg Phe Ser Ile Gly Phe Gly Lys Ala Leu 
35 	 40 	 45 
Trp Arg Arg Thr Asp Lys Leu Gly Thr Glu Tyr Val Ile Ala Leu Ile 
50 	 55 	 60 
Pro Leu Gly Gly Tyr Val Lys Met Leu Asp Glu Arg Ala Glu Pro Val 
65 	 70 	 75 	 80 
Val Pro Glu Leu Arg His His Ala Phe Asn Asn Lys Ser Val Gly Gin 
85 	 90 	 95 
Arg Ala Ala Ile Ile Ala Ala Gly Pro Val Ala Asn Phe Ile Phe Ala 
100 	 105 	 110 
Ile Phe Ala Tyr Trp Leu Val Phe Ile Ile Gly Val Pro Gly Val Arg 
115 	 120 	 125 
Pro Val Val Gly Glu Ile Ala Ala Asn Ser Ile Ala Ala Glu Ala Gin 
130 	 135 	 140 
Ile Ala Pro Gly Thr Glu Leu Lys Ala Val Asp Gly Ile Glu Thr Pro 
145 	 150 	 155 	 160 
Asp Trp Asp Ala Val Arg Leu Gin Leu Val Asp Lys Ile Gly Asp Glu 
165 	 170 	 175 
Ser Thr Thr Ile Thr Val Ala Pro Phe Gly Ser Asp Gin Arg Arg Asp 
180 	 185 	 190 
Val Lys Leu Asp Leu Arg His Trp Ala Phe Glu Pro Asp Lys Glu Asp 
195 	 200 	 205 
Pro Val Ser Ser Leu Gly Ile Arg Pro Arg Gly Pro Gin Ile Glu Pro 
210 	 215 	 220 
Val Leu Glu Asn Val Gin Pro Asn Ser Ala Ala Ser Lys Ala Gly Leu 
225 	 230 	 235 	 240 
Gin Ala Gly Asp Arg Ile Val Lys Val Asp Gly Gin Pro Leu Thr Gin 
245 	 250 	 255 
Trp Val Thr Phe Val Met Leu Val Arg Asp Asn Pro Gly Lys Ser Leu 
260 	 265 	 270 
Ala Leu Glu Ile Glu Arg Gin Gly Ser Pro Leu Ser Leu Thr Leu Ile 
275 	 280 	 285 
Pro Glu Ser Lys Pro Gly Asn Gly Lys Ala Ile Gly Phe Val Gly Ile 
290 	 295 	 300 
Glu Pro Lys Val Ile Pro Leu Pro Asp Glu Tyr Lys Val Val Arg Gin 
305 	 310 	 315 	 320 
Tyr Gly Pro Phe Asn Ala Ile Val Glu Ala Thr Asp Lys Thr Trp Gin 
325 	 330 	 335 
Leu Met Lys Leu Thr Val Ser Met Leu Gly Lys Leu Ile Thr Gly Asp 
340 	 345 	 350 
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Val Lys Leu Asn Asn Leu Ser Gly Pro Ile Ser Ile Ala Lys Gly Ala 
355 	 360 	 365 
Gly Met Thr Ala Glu Leu Gly Val Val Tyr Tyr Leu Pro Phe Leu Ala 
370 	 375 	 380 
Leu Ile Ser Val Asn Leu Gly Ile Ile Asn Leu Phe Pro Leu Pro Val 
385 	 390 	 395 	 400 
Leu Asp Gly Gly His Leu Leu Phe Leu Ala Ile Glu Lys Ile Lys Gly 
405 	 410 	 415 
Gly Pro Val Ser Glu Arg Val Gin Asp Phe Cys Tyr Arg Ile Gly Ser 
420 	 425 	 430 
Ile Leu Leu Val Leu Leu Met Gly Leu Ala Leu Phe Asn Asp Phe Ser 
435 	 440 	 445 
Arg Leu 
450 
<210> SEQ ID NO 19 
<211> LENGTH: 450 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic MucP peptide 
<400> SEQUENCE: 19 
Met Ser Ala Leu Tyr Met Ile Val Gly Thr Leu Val Ala Leu Gly Val 
1 	 5 	 10 	 15 
Leu Val Thr Phe His Glu Phe Gly His Phe Trp Val Ala Arg Arg Cys 
20 	 25 	 30 
Gly Val Lys Val Leu Arg Phe Ser Val Gly Phe Gly Thr Pro Leu Val 
35 	 40 	 45 
Arg Trp His Asp Arg His Gly Thr Glu Phe Val Val Ala Ala Ile Pro 
50 	 55 	 60 
Leu Gly Gly Tyr Val Lys Met Leu Asp Glu Arg Glu Ala Glu Val Pro 
65 	 70 	 75 	 80 
Ala His Leu Leu Glu Gin Ser Phe Asn Arg Lys Thr Val Arg Gin Arg 
85 	 90 	 95 
Ile Ala Ile Val Ala Ala Gly Pro Ile Ala Asn Phe Leu Leu Ala Ile 
100 	 105 	 110 
Leu Phe Phe Trp Val Val Ala Leu Leu Gly Ser Gin Gin Val Arg Pro 
115 	 120 	 125 
Val Ile Gly Ser Val Ala Pro Glu Ser Leu Ala Ala Gin Ala Gly Leu 
130 	 135 	 140 
Glu Ala Gly Gin Glu Leu Leu Ala Val Asp Gly Glu Pro Val Thr Gly 
145 	 150 	 155 	 160 
Trp Asn Gly Val Asn Leu Gin Leu Val Arg Arg Leu Gly Glu Ser Gly 
165 	 170 	 175 
Thr Leu Glu Val Arg Val Gin Glu Lys Gly Ser Asn Val Asp Ser Thr 
180 	 185 	 190 
His Gin Val Arg Leu Asp Gly Trp Leu Lys Gly Glu Asp Asn Pro Asp 
195 	 200 	 205 
Pro Ile Ala Ser Leu Gly Ile Arg Pro Trp Arg Pro Ala Leu Pro Pro 
210 	 215 	 220 
Val Leu Ala Glu Leu Asp Pro Lys Gly Pro Ala Gin Ala Ala Gly Leu 
225 	 230 	 235 	 240 
Lys Leu Gly Asp Arg Leu Gin Ser Ile Asp Gly Ile Ala Val Asp Asp 
245 	 250 	 255 
Trp Gin Gin Val Val Asp Ser Val Arg Ala Arg Pro Gly Gin Arg Val 
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260 	 265 	 270 
Gin Leu Lys Val Leu Arg Asp Gly Glu Val Leu Asp Val Ala Leu Glu 
275 	 280 	 285 
Leu Ala Val Arg Gly Glu Gly Lys Ala Arg Ser Gly Tyr Met Gly Ala 
290 	 295 	 300 
Gly Val Ala Gly Thr Glu Trp Pro Ala Glu Met Leu Arg Glu Val Ser 
305 	 310 	 315 	 320 
Tyr Gly Pro Leu Glu Ala Val Gly Gin Ala Leu Ser Arg Thr Trp Thr 
325 	 330 	 335 
Met Ser Leu Leu Thr Leu Asp Ser Ile Lys Lys Met Leu Leu Gly Glu 
340 	 345 	 350 
Leu Ser Val Lys Asn Leu Ser Gly Pro Ile Thr Ile Ala Lys Val Ala 
355 	 360 	 365 
Gly Ala Ser Ala Gin Ser Gly Val Gly Asp Phe Leu Asn Phe Leu Ala 
370 	 375 	 380 
Tyr Leu Ser Ile Ser Leu Gly Val Leu Asn Leu Leu Pro Ile Pro Val 
385 	 390 	 395 	 400 
Leu Asp Gly Gly His Leu Leu Phe Tyr Leu Val Glu Trp Val Arg Gly 
405 	 410 	 415 
Arg Pro Leu Ser Glu Arg Val Gin Ala Trp Gly Met Gin Ile Gly Ile 
420 	 425 	 430 
Ser Leu Val Val Gly Val Met Leu Leu Ala Leu Val Asn Asp Leu Ser 
435 	 440 	 445 
Arg Leu 
450 
<210> SEQ ID NO 20 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 20 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 21 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 21 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
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Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 22 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 22 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 23 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 23 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 24 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 24 
Met Asn Ser Ala Leu Leu Leu Leu Asn Ala Ile Ala Ile Ala Val Leu 
1 	 5 	 10 	 15 
Ala Ala Phe His Phe Gin Pro Ala Asp Asp Ala Ala Pro Gly Gly Thr 
20 	 25 	 30 
Ser Phe Ala His Tyr Gin Gin Arg Leu Ala Pro Gin Leu Ala Val Met 
35 	 40 	 45 
Asn Thr Gin Ile Glu Pro Gly Ser Val Thr Arg Val Thr Gin Gly Lys 
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50 	 55 	 60 
Ala Ser Gin Gin Pro Ala Ala Ala Pro Thr Glu Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 25 
<211> LENGTH: 75 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 25 
Met Asn Ser Ala Leu Val Phe Ala Asn Ala Ile Ala Leu Ala Val Leu 
1 	 5 	 10 	 15 
Met Gly Phe His Leu Val Pro Glu Asp Asn Glu Lys Val Ala Gly Arg 
20 	 25 	 30 
Met Pro His Tyr Leu Gin Val Gin Lys Ala Pro Gin Trp Ala Val Leu 
35 	 40 	 45 
Ser Asp Gin Ser Phe Ala Pro Gin Ala Val Ser Gin Ser Glu Gin Ala 
50 	 55 	 60 
Leu Pro Ala His Ser Thr Glu Arg Leu Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 26 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE: 26 
Met Asn Lys Thr Leu Ser Val Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe His Asp Ser Gly Ala Ser Asp Thr Gin Val Asn 
20 	 25 	 30 
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Ile Ala Ser Ala Ala Val Leu Ala Asn Asp Asp 
50 	 55 	 60 
Asp Asp Ser Leu Gin Met Pro Arg Ala Glu Gin Arg Trp Ile Phe 
65 	 70 	 75 
<210> SEQ ID NO 27 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE: 27 
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe Gin Asp Ser Gly Ala Lys Asp Thr Gin Val Thr 
20 	 25 	 30 
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Val Leu Ala Thr Asp Asp 
50 	 55 	 60 
Asp Ala Ser Val Gin Met Pro Arg Ala Glu Gin Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 28 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
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<400> SEQUENCE: 28 
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe Gin Asp Ser Gly Ile Lys Asp Ala Gin Ala Ile 
20 	 25 	 30 
Thr Pro Ala Pro Val His His Gin Ile Ser Gin Ala Pro Lys Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Met Leu Ala Asn Asp Asp 
50 	 55 	 60 
Asp Glu Ser Leu Gin Phe Pro Arg Ala Glu Gin Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 29 
<211> LENGTH: 389 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 29 
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val 
1 	 5 	 10 	 15 
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu 
20 	 25 	 30 
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu 
35 	 40 	 45 
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro 
50 	 55 	 60 
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His 
65 	 70 	 75 	 80 
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu 
85 	 90 	 95 
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met 
100 	 105 	 110 
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala 
115 	 120 	 125 
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin 
130 	 135 	 140 
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp 
145 	 150 	 155 	 160 
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg 
165 	 170 	 175 
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin 
180 	 185 	 190 
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly 
195 	 200 	 205 
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe 
210 	 215 	 220 
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly 
225 	 230 	 235 	 240 
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly 
245 	 250 	 255 
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile 
260 	 265 	 270 
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala 
275 	 280 	 285 
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly 
US 8,399,649 B2 
69 	 70 
-continued 
290 	 295 	 300 
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly 
305 	 310 	 315 	 320 
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser 
325 	 330 	 335 
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin 
340 	 345 	 350 
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr 
355 	 360 	 365 
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys 
370 	 375 	 380 
Gin Asp Gly Gly Glu 
385 
<210> SEQ ID NO 30 
<211> LENGTH: 389 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 30 
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val 
1 	 5 	 10 	 15 
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu 
20 	 25 	 30 
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu 
35 	 40 	 45 
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro 
50 	 55 	 60 
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His 
65 	 70 	 75 	 80 
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu 
85 	 90 	 95 
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met 
100 	 105 	 110 
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala 
115 	 120 	 125 
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin 
130 	 135 	 140 
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp 
145 	 150 	 155 	 160 
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg 
165 	 170 	 175 
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin 
180 	 185 	 190 
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly 
195 	 200 	 205 
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe 
210 	 215 	 220 
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly 
225 	 230 	 235 	 240 
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly 
245 	 250 	 255 
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile 
260 	 265 	 270 
Glu His Gly Gin Val Ile Arg Gly Trp Leu Gly Val Glu Val Lys Ala 
US 8,399,649 B2 
71 	 72 
-continued 
275 	 280 	 285 
Leu Thr Pro Glu Leu Ala Glu Ser Leu Gly Leu Gly Glu Thr Ala Gly 
290 	 295 	 300 
Ile Val Val Ala Gly Val Tyr Arg Asp Gly Pro Ala Ala Arg Gly Gly 
305 	 310 	 315 	 320 
Leu Leu Pro Gly Asp Val Ile Leu Thr Ile Asp Lys Gin Glu Ala Ser 
325 	 330 	 335 
Asp Gly Arg Arg Ser Met Asn Gin Val Ala Arg Thr Arg Pro Gly Gin 
340 	 345 	 350 
Lys Ile Ser Ile Val Val Leu Arg Asn Gly Gin Lys Val Asn Leu Thr 
355 	 360 	 365 
Ala Glu Val Gly Leu Arg Pro Pro Pro Ala Pro Ala Pro Gin Gin Lys 
370 	 375 	 380 
Gin Asp Gly Gly Glu 
385 
<210> SEQ ID NO 31 
<211> LENGTH: 389 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 31 
Met Pro Lys Ala Leu Arg Phe Leu Gly Trp Pro Val Leu Val Gly Val 
1 	 5 	 10 	 15 
Leu Leu Ala Leu Leu Ile Ile Gin His Asn Pro Glu Leu Val Gly Leu 
20 	 25 	 30 
Pro Arg Gin Glu Val His Val Glu Gin Ala Pro Leu Leu Ser Arg Leu 
35 	 40 	 45 
Gin Glu Gly Pro Val Ser Tyr Ala Asn Ala Val Ser Arg Ala Ala Pro 
50 	 55 	 60 
Ala Val Ala Asn Leu Tyr Thr Thr Lys Met Val Ser Lys Pro Ser His 
65 	 70 	 75 	 80 
Pro Leu Phe Asp Asp Pro Met Phe Arg Arg Phe Phe Gly Asp Asn Leu 
85 	 90 	 95 
Pro Gin Gin Lys Arg Met Glu Ser Ser Leu Gly Ser Ala Val Ile Met 
100 	 105 	 110 
Ser Ala Glu Gly Tyr Leu Leu Thr Asn Asn His Val Thr Ala Gly Ala 
115 	 120 	 125 
Asp Gin Ile Ile Val Ala Leu Arg Asp Gly Arg Glu Thr Ile Ala Gin 
130 	 135 	 140 
Leu Val Gly Ser Asp Pro Glu Thr Asp Leu Ala Val Leu Lys Ile Asp 
145 	 150 	 155 	 160 
Leu Lys Asn Leu Pro Ala Met Thr Leu Gly Arg Ser Asp Gly Ile Arg 
165 	 170 	 175 
Thr Gly Asp Val Cys Leu Ala Ile Gly Asn Pro Phe Gly Val Gly Gin 
180 	 185 	 190 
Thr Val Thr Met Gly Ile Ile Ser Ala Thr Gly Arg Asn Gin Leu Gly 
195 	 200 	 205 
Leu Asn Thr Tyr Glu Asp Phe Ile Gin Thr Asp Ala Ala Ile Asn Phe 
210 	 215 	 220 
Gly Asn Ser Gly Gly Ala Leu Val Asp Ala Ala Gly Asn Leu Ile Gly 
225 	 230 	 235 	 240 
Ile Asn Thr Ala Ile Phe Ser Lys Ser Gly Gly Ser Gin Gly Ile Gly 
245 	 250 	 255 
Phe Ala Ile Pro Thr Lys Leu Ala Leu Glu Val Met Gin Ser Ile Ile 
